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Folate Bioavailability. In vitro Experiments and Human Trials  
Abstract 
An inadequate folate status is associated with increased risk of anaemia and neural 
tube defects. In many countries a folate intake below recommendations has been 
reported for women in childbearing age. However, data on folate intake and status 
are not always associated, since factors other than intake, e.g. bioavailability, affect 
folate status.  
This thesis studied the bioavailability of folate using in vivo and in vitro models. 
The effect of two pieces of Swedish nutritional advice on folate status of healthy 
women was assessed in a 12-week randomised controlled intervention trial. By 
combining a human plasma area under the curve (AUC)/ileostomy model with a 
stable isotope technique, the bioavailability of wholemeal bread fortified with 
reduced folate (5-CH3-H4folate) or folic acid was determined. In vitro effects of the 
food matrix on bioaccessibility and uptake of reduced folates were studied using a 
dynamic gastrointestinal model (TIM) and Caco-2 cells.  
The intervention breakfast diet (contributing ~1/3 of recommended daily folate 
intake) significantly improved folate status of the women, indicating a high folate 
bioavailability. The bread intervention diet (contributing ~1/5 of recommended 
daily folate intake) maintained folate and decreased homocysteine concentrations.  
Based on folate content in stomal effluent, the bioavailability of both folate 
fortificants tested was similarly high (~90%) but plasma kinetics differed significantly 
depending on ingested folate form. Data from in vitro TIM and Caco-2 cell 
experiments showed an inhibitory effect (~25%) of the bread matrix on 
bioaccessibility and uptake of reduced folates, which was higher than in vivo 
findings.  
Overall, data from these in vivo and in vitro studies suggest that the bioavailability 
of reduced folate is high and comparable to that of synthetic folic acid. Food matrix 
effects,  e.g. of bread or a typical breakfast meal, on folate bioavailability seem 
negligible at physiological folate intake doses. 
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gastrointestinal model, Caco-2 cell, food folate intake stable isotope-labell 
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1  Background 
Nearly 80 years ago, Lucy Wills treated anaemic pregnant Indian women 
with a yeast extract (Wills et al., 1937). The active compound in the yeast 
was later identified as folate, at that time called antianaemia factor (Pfiffner et 
al., 1945). As folates are required for cellular replication and thereby 
production of red blood cells, folate deficiency causes anaemia.  
Folate requirement is now known to be higher in life-stages with intense 
cell division, e.g. during pregnancy. The preventive effect of a high folic 
acid intake against neural tube defects (NTD) is considered one of the most 
important nutritional discoveries between 1976-2006 (Katan et al., 2009). 
This is due to the severity of NTD rather than the incidence rate, which is 
~0.1% of births in Europe (Busby et al., 2005). Children born with NTD 
often die before the age of 5 (~50%) or have mobility and intellectual 
disabilities (Sutton et al., 2008).  
An inadequate intake of folates is the only risk factor for NTD that can 
be directly affected (Mitchell et al., 2004). Unfortunately, folates and vitamin 
D are the only vitamins for which a varied diet cannot be assumed to 
completely cover the nutrient requirements of the entire population in the 
Nordic countries (NNR, 2005). Reported folate intake in women of 
childbearing age is lower than recommended in Scandinavia (NNR, 2005) 
but also in several other countries world-wide, e.g. the Netherlands (van de 
Rest et al., 2007) and Thailand (Sirikulchayanonta et al., 2004). 
Fruit and vegetables are good folate sources and are commonly consumed 
by the Swedish population (Becker & Pearson, 2003). However, the most 
popular fruit and vegetables, i.e. tomato, apple and pear, hardly contain any 
folates. In addition, consumption of very good folate sources, such as pulses, 
is almost negligible (Becker & Pearson, 2003). Intake of folates is further 
reduced by folates being greatly unstable molecules (Figure 1), resulting in   14 
average 30% losses of vitamin activity during food processing (Bergström, 
1994). 
The most stable folate form, i.e. folic acid (Figure 1), is cheap to synthesise 
and is thus frequently used for food fortification and in supplements. 
National introduction of folic acid-fortified staple foods, e.g. in the USA and 
Canada, has effectively reduced the prevalence of NTD (Mosley et al., 2009; 
Liu et al., 2004). On the other hand fortification is questioned, as a high 
folic acid intake is suggested to accelerate development of e.g. colorectal 
cancer (Kim, 2007). 
Recommendations are met more easily through consumption of folic acid-
fortified foods, partly due to the higher bioavailability of folic acid compared 
with food folates. A food folate bioavailability value of 50% of that of folic 
acid supplements is commonly assumed when establishing recommendations 
and upper limits of intake e.g. at Centre for Disease Control in USA (CDC, 
2009) and in the Nordic Nutrition Recommendations (NNR, 2005). The 
50% level must be considered a rough estimate, as data on food folate 
bioavailability vary substantially from 30% (Hannon-Fletcher et al., 2004) to 
98% (Brouwer et al., 1999). The large discrepancy in estimated 
bioavailability could be caused by different test foods, e.g. the food matrix 
may entrap folates and food components may affect folate stability and 
inhibit absorption. Different absorption and distribution kinetics for food 
(reduced) folates and folic acid have also been shown (Wright et al., 2005). 
Moreover, differences in study design, study population and analytical 
methods may affect estimated bioavailability. 
1.1  Metabolism of folates 
Unlike plants and bacteria, mammals cannot synthesise folates and hence 
intake through food or supplements is required (Figure 2). Assessment of 
data on human in vivo folate production, distribution and excretion (Figure 
2) is difficult and hence the limited data summarised in Figure 2 mostly 
originate from ingestion of radio- or stable isotope-labelled folic acid and are 
not always representative. 
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The IUPAC nomenclature (Blakley, 1988) of 
folates is ‘a group of heterocyclic compounds based 
on a 4-[(pteridin-6-ylmethyl)amino]benzoic acid 
skeleton conjugated with one or more L-glutamate 
units’. Over 150 folate forms exist in theory, but in 
most animals and plants less than 50 are found. In 
nature, folates exist in reduced form but during 
sample preparation and storage folates may be partly 
or totally oxidised.  
 
Causes of structural variations are: 
1. Oxidation state of the pterin ring.  
2. Number of glutamate (Glu) residues, often 3-11.  
3. One-carbon substituents at N-5 and/or N-10.  
4. Diastereoisomery, two chiral centres (*) exist and 
determine folate activity. For H4folate, 5-CH3-
H4folate and 5-HCO-H4folate, (6S) has vitamin 
activity, while for 10-HCO-H4folate, (6R) has.  
Oxidisation state and substitution lead to increased 
stability of the folate molecule. 
 
Vitamin activity may be lost by oxidative 
cleaving at the 9C-10N bond resulting in a pterin 
and para-aminobenzoylglutamate (pABG) molecule.  
 
Many folate forms are prone to interconversion, e.g. caused by oxygen or changes in pH. For 
folates often found in foods, common interconversions are: 
5-CH3-H4folate
10-HCO-H4folate
5-CH3-H2folate pterin+pABG
10-HCO-H2folate
antioxidant
O2 10-HCO-folic acid
O2
5-HCO-H4folate 5,10-CH-H4folate
pH<2
10-HCO-H4folate
pH>2
pH<2
pH>2
O2
antioxidant
antioxidant
pH<2
 
Figure 1. Structure, nomenclature and interconversion of synthetic folic acid and common 
food folate forms summarised from Gregory (1996) and Blakley (1988).    16
Figure 2. Schematic overview of the human folate pool, estimated sources of intake and excretion 
1Conversion of g to mol by multiplying by 0.441
-1. 
2Post-fortification (after 1998). 
2Recommended daily intake is 300-400 µg /day (700-900 nmol). 1 = stomach; 2 = small intestine; 3 = colon; 4= liver; 5 
= gall bladder; 6 = circulation; 7 = kidney 
Sources Body  pools  Excretion 
A
B
D
C
E/F
G
H
I J
1
2
3
4
5
7
6
 
A. Dietary intake
1,2  
USA
2: ~715-3135 nmol/day 
(Choumenkovitch et al., 2002).    
European countries: ~420-1050 
nmol/day (Dhonukshe-Rutten 
et al., 2009). 
B. Microbial synthesis 
~25-100 nmol/day in infants 
(Kim et al., 2004). 
C. Absorption of food folate 
~50-98% (Winkels et al., 2007; 
Witthöft et al., 2006; Lin et al., 
2004; Konings et al., 2002; 
Sauberlich et al., 1987). 
D. Absorption in colon 
Physiological doses (684 nmol) 
are absorbed in colon after 
caecal infusion. 
(Aufreiter et al., 2009) 
E. Plasma
1 
USA
2: ~28 nmol/L  
(McDowell et al., 2008).                       
European countries: ~7-20 nmol/L 
(Dhonukshe-Rutten et al., 2009). 
F. Erythrocytes
1 
USA:~ 600 nmol/L  
(McDowell et al., 2008).                       
Denmark: ~820 nmol/L  
(Bor et al., 2008). 
G. Bile 
~90 nmol/L (Gregory & Quinlivan, 
2002). Reabsorption of bile folate is 
estimated to be 96% (Lin et al., 2004). 
H. Liver
 
~18±6 nmol/g (Hoppner & Lampi, 
1980) (liver weight ~1350 g). 
Assumed to comprise ~50% of the 
folate pool (Gregory et al., 1998).  
I. Faeces
1 
~415 nmol/day adults 
(Lin et al., 2004), 
~100 nmol/day infants 
(Kim et al., 2004). 
J. Urine 
~3-75 nmol intact folate 
/day (Gregory et al., 
1998). 
~330 nmol pABG/day 
(Gregory et al., 1998).  
<5 % of an ingested folate 
dose is excreted as intact 
folate (Lin et al., 2004; 
Witthöft et al., 2003; 
Rogers et al., 1997)  
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Folate absorption  
Folates are absorbed as monoglutamyl folates, mainly in the jejunum after 
cleavage of the polyglutamic chain by intestinal γ-glutamyl hydrolase 
(Halsted, 1990). Folate absorption is optimal at pH 6.3 (Russell et al., 1979). 
As folates are charged and thereby hydrophilic in the neutral pH of the 
intestine (Figure 3), passive diffusion across the cell-membrane is limited 
(Zhao et al., 2009). Instead, nearly all absorption (Figure 3) occurs actively 
by: 
 
1.  Transport across the luminal membrane by highly specific transporters, 
mainly the protein-coupled folate transporter (PCFT) (Qiu et al., 2006). 
2.  Retention within the enterocyte, where absorbed folates are converted 
into 5-CH3-H4folate by dihydrofolate reductase (DHFR) and 
methyltetrahydrofolate reductase (MTHFR) (Chanarin & Perry, 1969).  
3.  Transport across the basolateral membrane into plasma by less specific 
transporters, e.g. multidrug resistance associated proteins (MRP) (Assaraf, 
2006). 
The affinities of folate receptors and carriers (transporters) vary with pH and 
thus different transporters are important in different cells (Figure 3). In 
addition, affinities vary between folate forms, being higher to reduced folates 
than folic acid for both PCFT and RFC (Zhao et al., 2009). In contrast, 
affinity to folic acid is higher for FR α & ß (Zhao et al., 2009; Assaraf, 2006; 
Nygren-Babol et al., 2005). 
The glutamic chain added by folylpolyglutamate synthetase (Figure 3, H) 
causes cellular retention of folates by decreasing affinity to the efflux 
transporters (Figure 3, I), as well as increasing binding affinity to enzymes in 
folate metabolism (Quinlivan et al., 2006).  
Folate absorption may also occur in the colon (Figure 2) (Aufreiter et al., 
2009). Although colon absorption rate has been found to be ~50 times 
lower than estimated in the small intestine, it may contribute significantly to 
total folate absorption since the transit time in the colon is longer (~15 
times) and due to the presence of microbial folate production (Aufreiter et 
al., 2009). Nearly 70 years ago, microbial synthesis of folates in mammals 
was suggested (Mitchell et al., 1941), which was later estimated to about 25-
100 nmol/d in infants (Kim et al., 2004). The relevance for folate status of 
folates synthesised in the colon is unknown but bacterially synthesised folates 
has been shown to be bioavailable in humans (Camilo et al., 1996) and pigs 
(Asrar & O'Connor, 2005).   
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Figure 3. Intestinal absorption of food folates (modified from review by Zhao et al., 2009)  
A. γ-glutamyl hydrolase, cleaves the polyglutamic chain.  
B. Reduced folate carrier (RFC), expressed in e.g. the colon, small intestine, liver, kidney 
and blood brain barrier and has pH optimum 7.4.  
C. Protein-coupled folate transporter (PCFT), expressed in e.g. the small intestine, liver, 
kidney, placenta, brain and proximal colon and has pH optimum 5.5.  
D. Folate receptors (FR) α & ß, FRα expressed in e.g. the kidney, uterus and placenta and 
FRß in e.g. the placenta, spleen and thymus. FR have pH optimum 6.0-6.5.  
E. Passive diffusion is limited.  
F. Dihydrofolate reductase (DHFR).  
G. Methylenetetrahydrofolate reductase (MTHFR).  
H. Folylpolyglutamate synthetase (FPGS).  
I. Multidrug resistance associated proteins (MRP). 
 
Distribution and physiological function of folates 
After absorption, folates are transported to the liver (Figure 2), which is 
estimated to comprise 50% of the total folate body pool (Gregory et al., 
1998; Herbert, 1987). The liver folate pool is partly secreted (intact or as 
inactive metabolites) into bile (Herbert, 1987). Reabsorption of folates from 
bile in the gastrointestinal tract (Figure 2) is suggested to blunt between-
meal fluctuations in folate supply to cells (Lin et al., 2004). However, 
estimations of folate content in bile vary greatly from 227 nmol/d (Herbert, 
1987) to 5300 nmol/d (Lin et al., 2004). As a consequence, the estimated 
size of the total human body pool of folate (Figure 2) varies from 17 to 225 
mmol (Lin et al., 2004; Gregory et al., 2001; Herbert, 1987). 
Between 10-20% of absorbed folates are estimated to be retained in the 
liver in the so-called first-pass effect (Gregory, 1995). Remaining absorbed  
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folates are transported to other tissues with the systemic circulation. In 
plasma, folates are partly protein-bound, mainly to albumin (50% of bound 
folates) but also to soluble folate binding proteins (Shane, 1995). 
In the cells, folate polyglutamates are retained and used in the nucleus as 
substrates in both nucleotide synthesis and the methylation cycle (Figure 4). 
H4folate-polyglutamates are required for pyrimidine and purine synthesis, 
and thus DNA and RNA production, by providing one-carbon atoms.  
H4folate-polyglutamates are also involved in amino acid synthesis by 
accepting a one-carbon group (-CH3) from the amino acid serine, which is 
then converted into glycine (Wagner, 1995).  
In the methylation cycle, 5-CH3-H4folate donates a one-carbon group (-
CH3) to vitamin B12, which transfers it to homocysteine (Figure 4). 
Accumulation of homocysteine in the cell is thereby avoided and synthesis 
of amino acids maintained (Wagner, 1995).  
As folates are involved in cell replication, the first signs of deficiency 
appear in tissues with rapid cell turnover and in life stages with increased cell 
division, such as during pregnancy (Tamura & Picciano, 2006). Folate 
deficiency results in so-called megaloblastic anaemia caused by impaired 
synthesis of red blood cells (erythrocytes) due to lack of DNA (Herbert, 
1987). 
 
 
H4folate methionine
homocysteine 5-CH3-H4folate
purines
Nucleotide synthesis Methylation
formate
pyrimidines
H2folate
5,10-CH2-H4folate
10-HCO-H4folate
MTHFR
DHFR
TMP
UMP
TS
serine glycine
MS
betaine
vitamin B12
DMG
BHMT
 
Figure 4. Folate involvement in nucleotide synthesis and the methylation cycle (Reed et al., 
2006). End-products are in boxes. Enzymes are shaded  
BHMT = betaine-homocysteine methyltransferase; DHFR = dihydrofolate reductase;  DMG 
= dimethylglycine; MS = methionine synthase; MTHFR = methylenetetrahydrofolate 
reductase; TMP = thymidine monophosphate; TS = thymidylate synthase; UMP = uridine 
monophosphate.  
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Several factors are known to affect cellular folate metabolism:  
¾  A polymorphism in the enzyme methylenetetrahydrofolate reductase 
(677CÆT, Figure 3, G), which reduces enzyme activity to below 20% 
(Rozen, 2004) and thus increases the need for food folate or folic acid 
intake. Prevalence of this polymorphism varies worldwide from zero up 
to 32% (Wilcken et al., 2003). In Sweden, below 10% of the population 
are carriers of the 677CÆT-allele (Johansson et al., 2007; Ruiz et al., 
2007; Brattström et al., 1998).  
¾  A polymorphism in RFC (80AÆG, Figure 3, B) is a risk factor for NTD 
(Morin et al., 2003), either by interfering with intestinal absorption or 
folate transport, or both (Gregory et al., 2005).  
¾  The very rare disease ‘hereditary folate malabsorption’ is caused by 
insufficient absorption and transport of folate due to lack of PCFT 
(Figure 3, C) (Qiu et al., 2006). 
¾  Deficiency of vitamin B12 reduces the activity of methionine synthase 
(Figure 4, MS). Homocysteine and 5-CH3-H4folate are then accumulated 
in the cell, resulting in the so-called methyl trap and folate deficiency 
(Reed et al., 2006). 
Excretion of folates 
About 0.3-0.8% of the folate body pool has been estimated to be excreted 
intact or as catabolites daily (Gregory et al., 2001; Gregory et al., 1998). 
Excretion of intact folate with urine is as low as ~5% of ingested folates (Lin 
et al., 2004; Witthöft et al., 2003; Pfeiffer et al., 1997a; Rogers et al., 1997), 
due to folates being efficiently reabsorbed from primary urine by renal FRα 
(Zhao et al., 2009). At higher intakes of folates the excretion of intact folates 
increases. For example, in volunteers consuming 850 µg (1925 nmol) folic 
acid daily for 12 weeks, as much as 19% of total urinary folate excretion 
originated from the dose (isotope-labelled folic acid) (Gregory et al., 2001). 
The majority of folates excreted with urine (>300 nmol/day) occur as 
catabolites (Figure 2) and this fraction is not affected by e.g. increased daily 
folate intake (454-907 nmol/d) for 10 weeks (Gregory et al., 1998). 
In human faeces, folate content is about 400 nmol/day (Lin et al., 2004; 
Gregory & Quinlivan, 2002). Folates found in faeces originate from bacterial 
production, lysed enterocytes and gastrointestinal secretions such as bile 
(Gregory & Quinlivan, 2002). The 400 nmol folate excreted with faeces and 
stomal effluents daily contains about 20% non-absorbed food folates 
(Witthöft et al., 2006; Lin et al., 2004; Konings et al., 2002), which indicates 
incomplete bioavailability of folates.   
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1.2  Bioavailability of folates 
When formulating nutrition recommendations, a food folate bioavailability 
of 50% of that of folic acid is commonly used (CDC, 2009; NNR, 2005). 
One of the most cited references for this estimate is a 92-day trial assessing 
the minimum food folate intake required for normalisation of folate status 
after depletion (Sauberlich et al., 1987). Although the size of doses of food 
folate (n=3) and folic acid (n=4) varied greatly in that trial, it was estimated 
that availability of food folates was 50% of that of synthetic folic acid 
consumed with food (Sauberlich et al., 1987). Since that trial, several 
intervention studies assessing folate bioavailability have been carried out but 
the results are inconclusive (Table 1a and 1b). Variations in study design and 
definition of bioavailability complicate comparisons between long-term 
(Table 1a and 1b) and short-term (Table 2) experiments. 
Definitions used in this thesis are:  
¾  Folate absorption, in vivo - process by which folates proceed from site of 
administration to site of measurement (usually plasma) (Tozer & 
Rowland, 2006).  
¾  Folate bioavailability, in vivo - fraction of ingested folate that is absorbed 
and can be used for metabolic processes (Melse-Boonstra et al., 2004a). 
¾  Folate bioaccessibility, in vitro – fraction of a given amount folate that is 
released from [food] matrix and available for absorption (Minekus et al., 
1995).  
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Long-term bioavailability of folate  
Physiological effects of folates can only be studied using long-term 
intervention trials. Most intervention trials with folate have a duration of 4 
to 16 weeks and measure effects of the intervention diet as changes in folate 
status parameters (Table 1a and 1b). The most commonly used parameters 
are: 
¾  Fasting serum folate.  
¾  Erythrocyte folate, which reflects the average folate status during the 
lifespan of the erythrocyte (~120 days). 
¾  Plasma total homocysteine, which is inversely associated to folate status 
(see Figure 4).  
More than one status parameter is commonly assessed, which is appropriate 
since the sensitivity of parameters varies. For example, in a 4-week 
intervention trial the estimated bioavailability of food folate compared with 
folic acid was 78% based on serum folate concentrations, 98% based on 
erythrocyte folate concentrations and only 60% based on homocysteine 
concentrations (Brouwer et al., 1999). 
Several intervention trials report a low bioavailability of food folates 
compared with folic acid (Table 1a) (Hannon-Fletcher et al., 2004; Riddell 
et al., 2000; Cuskelly et al., 1996). However, the data are inconclusive as 
many other intervention studies show good bioavailability of food folates 
(Table 1b), either compared with a control group receiving no additional 
folate (Broekmans et al., 2000) or folic acid-fortified foods or supplements 
(Winkels et al., 2007; Fenech et al., 2005; Vahteristo et al., 2002). For 
example, bioavailability of equimolar doses of food folates (from rye 
products and orange juice) and folic acid (from fortified wheat bread) is 
equivalent based on similar improvements of folate status (n=64 women) 
(Vahteristo et al., 2002).  
Folate intervention trials can be hampered by uncontrolled consumption 
of other foods that are fortified or naturally rich in folates and lack of 
compliance. Hence it can be assumed that interventions with pharmaceutical 
preparations are less biased than those with food folate. For example, 
consumption of an intervention diet for several weeks may cause problems 
with compliance, e.g. during travel or if the diet needs to be purchased by 
the volunteers themselves, as in some intervention trials (Ashfield-Watt et 
al., 2003; Riddell et al., 2000).   
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Table 1a. Trials with food folate interventions having no significant effects on folate status, listed in order of increasing intervention dose 
Intervention diet  Dose (total
1) W  N
2  Age  Erythrocyte folate (nmol/L) p/s-folate (nmol/L)  tHcy (µmol/L)  Reference 
   folate µg/day        Baseline  End  Baseline  End  Baseline  End    
                       
Control  2  4  35, F  41±3
3      15±9
3  13  11±4
3  10  Bogers et  
5-a-day (fruit/veg)  43    36, F  42±4
3      17±9
3  16  10±3
3  10  al.,2007 
Control  0 (236)  16  43   -      26±8
3  25 9±3
3  9 Ashfield- 
5-a-day (fruit/veg)  63 (306)    41  -      26±7
3  28♦ 10±4
3  9 Watt  et al., 2003 
Control  0 (186)
3    18, M  23-39
4      16±9
3  15  12±4
3  12  Hannon- 
Spinach  200 (384)  4  18, M  23-39
4      14±5
3  15  12±3
3  12  Fletcher et  
Yeast  200 (411)    19, M  23-39
4      15±7
3  18  12±3
3  11  al., 2004 
Control  23 (210)  12  9, F  17-40
4 709±157
3,5 729
5        Cuskelly et  
High folate diet  201 (410)    10, F  17-40
4 797±200
3,5 857
5        al., 1996 
Control  0 (227)  12  15  36-71
4  539±166
3  537  15 (12-18)
6  14
6  12 (11-14)
6  12
6  Riddell et  
High folate diet   ~350 (707)    15  36-71
4  571±162
3  643  15 (13-17)
6  22
6♦  11 (9-12)
6  10
6  al., 2000 
F = female; M = men; W = week; Veg = vegetables. 
1Estimated by dietary recall (total folate intake not reported but estimated as dose + folate intake at 
screening).
 2Female and men unless otherwise stated. 
3Mean±SD. 
4Age reported as inclusion criteria. 
5Erythrocyte folate concentrations given in µg/L, 
calculated to nmol/L (0.460
-1 nmol/µg). 
6Geometric means (95% CI). ♦Significant effect compared with control (P<0.05)   
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Table 1b. Trials with food folate interventions having significant effects on folate status, listed in order of increasing intervention dose 
Intervention diet  Dose (total
1)   W  N
2  Age  Erythrocyte folate (nmol/L) p/s-folate (nmol/L)  tHcy (µmol/L)  Reference 
   folate µg/day         Baseline  End  Baseline
2 End Baseline
2 End     
                      
Low folate diet   0 (131)  4  23  50±4
3     13±6
3 12 14±6
3 13  Broekmans   
500 g veg and fruits   97 (228)  4  24  49±6
3     16±10
3 16♦ 12±4
3 11♦  et al., 2000 
Folic acid-fortified bread   188 (461) 4  31  36±13
3  606±224
3  697* 12±5
3  16*     Vahteristo et  
Rye and orange juice  184 (461)    33  36±13
3  561±190
3  658*  10±3
3  13*      al., 2002 
Folic acid  150 (221)
4 4  15 19-48
5     12±4
3  15
  10±2
3 9  Winkels  et 
Veg, fruits and liver pâté  331 (427)
4   29  19-41
5     12±4
3 18♦
  10±3
3 9  al., 2007  
Control  0 (242)  4  14  60±15
3      18 (15-22)
6  18
6  14 (12-16)
6  14
6  Venn et al.,  
High folate diet  355 (618)    20  58±18
3      18 (16-19)
6  25
6♦  12 (11-13)
6  11
6♦  2002 
Control 0  (210)
4  4 22  23±8
3 347±79
3 345  13±3
3 13 10±3
3 11  Brouwer  et  
Veg and fruits  350 (560)
4   23 23±8
3 338±81
3 400♦ 14±3
3 20♦ 11±5
3 10♦  al., 1999 
Pericarp flour bread   223 (436)  16  25  48-56
5  497 (414-581)
6  578
6  13 (11-15)
6  14
6  10 (8-11)
6  8
6  Fenech et  
Aleurone flour bread   615 (836)    25  46-54
5  509 (434-584)
6  768
6♦  13 (10-16)
6  27
6♦  9 (8-10)
6  7
6♦  al., 2005 
Nd = no data; W = week; Veg = vegetables. 
1Estimated by dietary recall (total folate intake not reported but estimated as dose + folate intake at screening). 
2Female and men. 
3Mean±SD. 
4Folate dose is analysed and not estimated using dietary recall. 
5Range. 
6Geometric means (95% CI). *Significant effect 
within the group compared with baseline (P<0.05) ♦Significant effect compared with control (P<0.05) 
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Short-term bioavailability of folate 
Short-term bioavailability of food folate has been found to be incomplete 
compared with that of folic acid (Tamura & Stokstad, 1973). Since then, 
bioavailability has been extensively studied using a number of approaches for 
assessment, for example: 
 
¾  Plasma area under the curve (AUC) 
Post-dose plasma AUC is assumed to correspond to the folate fraction 
absorbed from a single dose. Data are commonly presented as relative 
absorption, which is the ratio between plasma AUC after a test dose and an 
oral or intravenous dose of folic acid (Table 2). This approach is only 
appropriate if the absorption and metabolism of folate forms in the test and 
reference dose are the same, which has been questioned for 5-CH3-H4folate 
and 5-HCO-H4folate versus folic acid (Wright et al., 2005). Therefore, so-
called apparent absorption accounting for the folate distribution volume in 
the body has been determined in some trials (Table 2) (Witthöft et al., 2006; 
Wright et al., 2005). 
 
¾  Urinary folate excretion ratio 
Folate bioavailability is assumed to correspond to the excretion in urine of 
[
13C]-labelled folate from an oral dose relative to that of [
2H]-folic acid from 
an intravenous dose. By using this so-called dual-label stable-isotope 
protocol, folate absorption of food folate and added fortificants has been 
estimated to be 37-153% (Finglas et al., 2002; Pfeiffer et al., 1997a; Rogers et 
al., 1997; Wei et al., 1996; Gregory et al., 1991). 
 
¾  Oral-faecal balance technique 
Folate bioavailability is assumed to be inversely correlated to folate content 
in stomal effluent or faeces, i.e. non-absorbed folate, after a given dose, 
commonly related to that after a folic acid supplement. Not all folates found 
in stomal effluents and faeces originate from non-absorbed ingested folate 
(Gregory & Quinlivan, 2002). Use of stable isotope-labelling allows to 
distinguish folate from the dose from endogenous folates from body stores 
(Lin et al., 2004; Buchholz et al., 1999). To account for folate in stomal 
effluents not deriving from the dose baseline excretion on a folate-free study 
day was assessed (Witthöft et al., 2006; Witthöft et al., 2003). Another 
approach is to report stomal effluent content after a certain dose relative to 
that after a dose of folic acid (Konings et al., 2002). Folate bioavailability 
from single doses of food folate has been estimated to be 50-90% by use of  
  26 
ileostomy models (Witthöft et al., 2006; Witthöft et al., 2003; Konings et al., 
2002; Wigertz, 1997). 
A common criticism of short-term protocols is the use of nonphysiological 
doses, or large portions of test foods that are not likely to be consumed in a 
meal by the general population, e.g. 30 grams of yeast (Tamura & Stokstad, 
1973) or 500 g of spinach (Prinz-Langenohl et al., 1999). Most models seem 
to be insufficiently sensitive to assess folate bioavailability from a single food 
under physiological conditions. To improve sensitivity, folate body stores 
can be presaturated with supplemental folic acid (Table 2) to minimise and 
standardise hepatic retention of absorbed folate from the dose (Tamura & 
Stokstad, 1973). Use of stable isotope-labelled folates (Table 2) also increases 
sensitivity, as it is possible to distinguish labelled folate from the dose and 
unlabelled folate from endogenous body stores (Wright et al., 2005; Wright 
et al., 2003; Rogers et al., 1997). However, unless intrinsic labelling is used 
(Wright et al., 2005), no data on absorption of native folates from a specific 
food matrix are obtained.  
Spinach is often used as a test food (Table 2) due to its high native folate 
content of nearly 200 µg/100g (NFA, 2009a). Similar post-dose plasma 
AUCs have been found after ingestion of nearly equimolar doses of spinach 
folate and supplemental folic acid (Table 2) (Konings et al., 2002; Prinz-
Langenohl et al., 1999), which is surprising with respect to the general 
assumption of lower bioavailability of food folates. Furthermore, estimated 
apparent absorption is reported to be significantly higher after ingestion of 
intrinsically stable isotope-labelled spinach compared with supplemental folic 
acid (Table 2) (Wright et al., 2005). Data on folate absorption from foods 
other than spinach are sparse, but plasma AUCs after ingestion of 
strawberries, broccoli and bread made from aleurone flour are reported to be 
similar to those for folate supplements (Table 2) (Witthöft et al., 2003; 
Fenech et al., 1999).  
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Table 2. Trials using plasma concentrations to assess relative food folate or fortificant bioavailability 
1App abs = apparent absorption, estimated by kinetic modelling (Wright et al., 2005).
 
2Number of sampling occasions 0-4 h post-dose in brackets. 
3Mean+SD or range. 
4No data 
on gender of volunteers.
 5Presaturation with ~1 mg (Witthöft et al., 2006) or 5 mg (Pentieva 
et al., 2004) folic acid/day from day -9 to day -2 prior to each test day. 
6Conversion factor 
from µg to nmol: 0.441
-1 nmol/µg (folic acid doses) and 0.460
-1 nmol/µg (plasma folate and 
5-CH3-H4folate doses). 
7Female and men reported separately 
  Dose 
nmol 
App abs
1 
or AUC 
Sampling 
duration 
(nr/4h)
2 
Female + 
men 
Age
3 Reference 
 
Apparent absorption (%) from supplements, fortified foods and food folate 
13C6-folic acid
  634 24% 8h  (8) 14
4  33±2 
13C6-5-HCO-H4folate
  500 38%
  8h (8)  14
4  33±2 
spinach 
15N1-7 folate   588  44%
  8h (8)  14
4  33±2 
Wright et al. 2005 
5-CH3-H4folate in 
fermented milk
5  
450
6  86% 10h  (7) 1+8  51-79 
Folic acid in bread
5   491
6  74% 10h  (7) 1+8  51-79 
Yeast
5  155
6  80% 10h  (7) 1+8  51-79 
Witthöft et al. 2006 
Size of AUC (h·nmol/L) from supplements and fortified foods 
13C6-folic acid 634  19  8h  (8)  10
4  31±1 Wright et al. 2003 
Folic acid
5  1134 146
  10h (6)  0+13  26±6  Pentieva et al. 2004 
Folic acid 
  1134  40   10h (6)  6+6  36-69  Konings et al. 2002 
Folic acid
  1193 37,  49
7   7h (3)  8+8  20-50  Fenech et al. 1999 
Folic acid  907  62   10h (4)  10+10  27±3  Prinz-Langenohl et 
al. 1999 
13C6-folic acid & 
2H2-
folic acid, i.v.  
1010 
226 
-
  9h (6)  2+2  20-35  Rogers et al. 1997 
13C6-5-HCO-H4folate 500  42
  8h (8)  10
4  31±1 Wright et al. 2003 
5-CH3-H4folate
5 1088  142  10h  (6)  0+13  26±6  Pentieva et al. 2004 
5-CH3-H4folate
5 830
6  44, 88
6  10h (7)  0+2  55, 77 
5-CH3-H4folate i.m.
5 830
6  111, 144
6  10h (7)  0+2  55, 77 
Witthöft et al. 2003 
Size of AUC (h·nmol/L) from food folates       
Broccoli
5 440  27,  41
6  10h (7)  0+2  55, 77  Witthöft et al. 2003 
Strawberries
5 450  32,  41
6  10h (7)  0+2  55, 77   
Spinach, monoglu-  820  31  10h (6)  6+6  36-69 
Spinach, polyglu-   990  27  10h (6)  6+6  36-69 
Konings et al. 2002 
 
Spinach   544& 
1088 
41, 71   10h (4)  10+10  27±3  Prinz-Langenohl et 
al. 1999 
Aleurone flour   1167  46, 38
7  7h (3)  8+8  20-50 
Wheat bran   213  8, 6
7   7h (3)  8+8  20-50 
Fenech et al. 1999 
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By measurement of folate content in faeces or stomal effluents, the non-
absorbed fraction after ingestion of folate-rich foods, fortified foods or 
supplements has been estimated at 8-23% (Witthöft et al., 2006; Konings et 
al., 2002; Lin et al., 2004; Buchholz et al., 1999), indicating a high folate 
bioavailability. A gap of up to 25% between absorbed (55-86%) and non-
absorbed folates has been reported (Witthöft et al., 2006). This could be 
explained by analytical errors, incomplete sample collection or, as suggested 
by Wright et al. (2005), hepatic folate retention during first passage. Wright 
et al. (2005) estimated the first-pass effect to be as much as 73% of absorbed 
folic acid, and 52% of absorbed intrinsically labelled spinach folate. 
Factors affecting bioavailability of folates 
Bioavailability of folate may be affected by so-called extrinsic factors, e.g. the 
food matrix and folate form, as well as host-related intrinsic factors such as 
gastrointestinal pH. 
The effect of the cereal matrix on folate bioavailability has been 
extensively studied as it is an appropriate matrix for folic acid fortification. 
Findings from short-term trials indicate an inhibitory effect of dietary fibre 
on folate bioavailability. For example, the relative increase in serum folate 
concentrations after single doses of 1000 µg (2265 nmol) folic acid was only 
~30% from a fortified whole wheat bread, which was significantly lower 
than the 50-60% assessed after ingestion of an eqimolar folic acid dose from 
fortified polished rice and maize porridge (Colman et al., 1975).  
The negative effect of dietary fibre content was confirmed using a dual-
label stable-isotope protocol in which relative urinary excretion ratio (page 
24) of physiological doses of folic acid (225 µg, 510 nmol) was lower from 
bran flakes rich in dietary fibre (~0.4) than from white bread (~0.7) (Finglas 
et al., 2002). However, in long-term trials, cereal foods rich in folate and 
dietary fibre have been reported to be as efficient as folic acid in improving 
the folate status of volunteers (Table 1b) (Fenech et al., 2005; Vahteristo et 
al., 2002). Furthermore, ingestion of dietary fibre has been correlated to 
serum folate concentrations in female adolescents (Houghton et al., 1997) 
and to folate intake in post-menopausal women (Ericson et al., 2007). 
Folate bioavailability from a single dose of 600 mL orange juice (840 
µg/1900 nmol) has also been shown to be low (~30%) compared with an 
oral dose of folic acid (Tamura & Stokstad, 1973). This was assumed to be 
caused  by a lowering of pH due to the large amount of ingested orange 
juice (Tamura & Stokstad, 1973). Wei & Gregory (1998) suggested that it 
was the organic anions in the orange juice that inhibited γ-glutamyl 
hydrolase activity and thereby potentially folate absorption. The possibility  
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that γ-glutamyl hydrolase might be a limiting factor in folate absorption in 
vivo was also indicated in a 12-week intervention study where bioavailability 
of folate polyglutamates was ~65% of that of folate monoglutamates (Melse-
Boonstra et al., 2004b). Furthermore, phenolic compounds in wine, beer 
and tea have been shown to reduce folic acid uptake into Caco-2 cells 
(Lemos et al., 2007).  
Other food components suggested to affect folate bioavailability are 
folate-binding proteins (FBP). The FBP present in e.g. plasma and milk have 
been suggested to stabilise folates in the gastrointestinal tract (Jones & 
Nixon, 2002). However, by using an in vitro model assessing release and 
stability of folates during passage through a simulated gastrointestinal tract 
(TIM), addition of FBP has been shown to reduce folate bioaccessibility 
from e.g. yoghurt (Arkbåge et al., 2003). This finding was confirmed in vivo, 
since apparent absorption of 5-CH3-H4folate fortificant was 16% lower and 
relative stomal excretion 9% higher when FBP was added to fermented milk 
(Witthöft et al., 2006).  
As previously mentioned, the bioavailability of folic acid supplements is 
considered superior. This might be explained by lack of matrix effects and 
that folic acid has no polyglutamic chain and hence γ-glutamyl hydrolase 
cannot be a limiting factor.  
Host-related intrinsic factors such as gastric pH and folate status may also 
affect absorption. Drugs or diseases causing increased gastric pH, e.g. antacids 
or atrophic gastritis, reduce folate absorption in vivo (Russell et al., 1988) and 
use of Caco-2 cells has shown that folic acid uptake is optimal at pH ~5.5 
(Mason et al., 1990). High exposure to folic acid can also reduce uptake by 
down-regulation of genes coding for folate absorption and transport (PCFT, 
RFC and FR, Figure 3, B-D) in Caco-2 and renal cells (Ashokkumar et al., 
2007). 
To summarise, several factors affecting human folate bioavailability have 
been found using in vivo and in vitro models. The potential underlying 
mechanisms were identified using in vitro and animal models.  
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1.3  Folate intake and status 
National intake studies in northern Europe indicate insufficient folate intake 
among women of childbearing age (Dhonukshe-Rutten et al., 2009). In 
Sweden, folate intake in this particular group is estimated to be about 60% 
of the recommended level (400 µg daily) (NNR, 2005; Becker & Pearson, 
2003). However, population-based estimates of folate intake are only as 
good as the national food data used (Gregory et al., 2005) and these data vary 
as a result of different methods for folate quantification, adjustment for 
preparation losses and due to natural variations in folate content in food 
products (Williamson & Buttriss, 2007; Hakala et al., 2003). 
Data on folate intake in the Swedish population (Table 3) are rather 
comprehensive due to the national intake surveys (Becker & Pearson, 2003; 
Becker, 1994) and the large cohorts (Ericson et al., 2007; Van Guelphen, 
2006; Larsson et al., 2004). Folate intake can be assessed using different 
methods, e.g. weighed food records, where volunteers weigh all foods and 
beverages consumed over a specific time period. A less burdensome method 
for volunteers is dietary recall interviews, which rely on the volunteers’ 
memory. Such interviews require skilled interviewers and are consequently 
costly for large studies (Pufulete et al., 2002). Therefore Food Frequency 
Questionnaires (FFQ) validated against other dietary assessment methods or 
biochemical parameters are commonly used for assessment of folate intake in 
epidemiology. FFQ are distributed to volunteers who mark intake frequency 
of common foods during a certain time period. Intake of nutrients is 
estimated by multiplying frequency by typical portion sizes and nutrient 
content in food (derived from food composition tables). As shown in Table 
3, folate intake estimated using FFQ are similar to those using other 
methods, which is partly due to use of the same food database (NFA, 
2009a).  
Recommended folate intake for women of childbearing age is 400 µg 
daily (NNR, 2005), an intake only reported for vegans (Table 3) (Larsson & 
Johansson, 2002). For adults the recommended daily intake is 300 µg 
(NNR, 2005) since this level has been shown sufficient to maintain good 
folate status (Prinz-Langenohl et al., 1999; Cuskelly et al., 1996; Gregory, 
1995; Herbert, 1987; Sauberlich et al., 1987).  
Folate intake by pregnant women (Åden et al., 2007) is only about 50% of 
the recommended 500 µg/day (NNR, 2005). The higher recommended 
intake for pregnant and nursing women is based on a metabolic study (84-d) 
where about 600 µg dietary folate equivalents (i.e. food folates) maintained  
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erythrocyte folate status in pregnant women (Caudill et al., 1997). Although 
the Swedish National Food Administration recommends that all women 
who might become pregnant consume folic acid supplements, none of the 
women in the trial by Åden et al. (2007) consumed folic acid supplements 
prior to pregnancy and only 12% consumed such supplements during 
pregnancy. 
 
Table 3. Estimated folate intake in Swedish women  
Method  Name of study  N  Region  µg/day  Reference 
    
   
National intake surveys     
   
7 d record  Riksmaten  626  Sweden  211 (142-294)
1  Becker & Pearson, 
2003 
7 d record  HULK  804  Sweden  183 (126-267)
1  Becker, 1994 
Cohort studies        
Diet-history 
method
2 
Malmö Diet and 
Cancer cohort 
11307 Malmö  287±318
3  Ericson et al., 2007 
65-84 FFQ  NSHDS  826  Umeå  226 (179-274)
4  Van Guelphen, 2006 
28 d record  129  211
4  Larsson et al., 2004 
96 FFQ 
The Swedish 
Mammography 
Cohort 
61084 
Uppsala/ 
Västman-
land 
178 (155-204)
4  Larsson et al., 2004 
Intake studies          
84 FFQ  -  49  Umeå  225±91
3,5  Åden et al., 2007 
24 h recall  -  50  Umeå  260±80
3,6  Åden et al., 2007 
Diet-history 
interview  - 
30 
30 
Umeå 
Umeå 
473±187
3,7  
226±73
3,8 
Larsson & Johansson, 
2002 
Intervention study        
FFQ 
- 
15 
14 
Uppsala 
Uppsala 
209 
221 
Johansson et al., 2002 
Johansson et al., 2002 
HULK = HUshållens Livsmedelsutgifter och Kostvanor; 
 NSHDS = Northern Sweden 
Health and Disease Study.
 11
st and 9
th deciles. 
2Combination of 7-day menu-book, 168 item 
FFQ and diet-history interview. 
3Mean±SD. 
4Median (Q1 and Q3) 
5Prior to pregnancy.
  6Mid-
gestation. 
7Vegans. 
8Omnivores   
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Data on folate status in Europe are less comprehensive, but for women of 
childbearing age high average erythrocyte folate concentrations (>800 
nmol/L) are reported from Ireland (Flynn et al., 2008) and Denmark (Bor et 
al., 2008), whereas concentrations in Germany (Thamm et al., 1999) are 
similar to those in the USA (~600 nmol/L) (McDowell et al., 2008).  
In the literature review carried out before a decision was made on 
whether to introduce folic acid fortification in Sweden (SBU, 2007), it was 
noted that data on the Swedish population were limited and the authors 
only refered to data from one case-control study (George et al., 2002), one 
cohort (Wahlin et al., 2002) and one intervention trial (Johansson et al., 
2002). Of these, only the case-control study could be considered 
representative, as intervention trials are not representative and as Wahlin et 
al. (2002) presented data which were not corrected for non-fasting sample 
collection. Table 4 summarises reported data on plasma folate and plasma 
total homocysteine in Sweden.  
For the representative studies, plasma folate concentrations were about 9 
nmol/L (deficiency <7 nmol/L) but in one cohort (NSHDS) nearly 1/3 of 
the participants were folate-deficient (Van Guelphen, 2006). For 
homocysteine, elevated concentrations - possibly due to chronic renal 
disease or malabsorption of vitamin B12 (Carmel et al., 2003) - were 
reported in study populations >70 years (Lewerin et al., 2005; Björkegren & 
Svardsudd, 2003) and occurred in as many as 50% of volunteers with normal 
folate status in one intervention trial (Lewerin et al., 2005). Therefore 
elevated homocysteine concentrations in the elderly must not be used as a 
marker of increased risk of cardiovascular disease (Carmel et al., 2003).  
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Table 4. Concentrations of plasma (or serum) folate and plasma total homocysteine as reported in 
Swedish trials. Mean±SD if not otherwise stated 
Study type  N  % 
Men 
Age Region  Folate 
nmol/L
1 
tHcy 
µmol/L
1 
Reference 
              
194 0  16±4
2 -  9±4
2 
185 100  16±4
2 -  10±4
2 
138 0  10±4
2 -  7±1
2 
Cohort  
European Youth 
Heart Study 
163 100  10±4
2 
County of 
Uppsala and 
Västmanland 
- 6±1
2 
Ruiz et al., 
2007  
329 0  <60  Umeå  9  (7-12)
3  9 (8-11)
3,4 
826 0  25-74
5  Umeå 9  (6-12)
3  9 (6-12)
3,4 
Cohort  
NSHDS 
1791 100 25-74
5 Umeå  8  (6-11)
3  10 (9-12)
3,4 
Van 
Guelphen, 
2006  
571 0  63±13
2 Skara  -  10±4
2,6  Cohort Skara 
Population Study  537 100  63±13
2 Skara  -  11±4
2,6 
Björck et al., 
2006  
Cohort  
Betula Project 
961 47  35-80
7  Umeå 18±11
2,8  18±11
2,8  Wahlin et al. , 
2001  
Cohort 161  43  77±6
2 Älvkarleby  9±4
2 18±7
2 Björkegren  & 
Svardsudd, 
2003 
Case-control 583  0  30  Uppsala  9
2,9  - George et al., 
2006 
Case-control 921  0  -  Uppsala  9±5
2,9  9±5
2 George et al., 
2002 
126 38  76±5
2 Göteborg  16±6
2 18±6
2  Intervention 
69 44  76±4
2 Göteborg  16±5
2 16±5
2 
Lewerin et al. 
2005 
15 0  23-50
7 Uppsala  16±5
2 9±2
2  Intervention 
14 0  23-50
7 Uppsala  19±5
2 8±2
2 
Johansson et 
al., 2002 
NSHDS, Northern Sweden Health and Disease Study. 
1Concentrations of folate and tHcy 
were determined with radiobinding assay unless otherwise stated.
 2Mean±SD. 
3Median (Q1 
and Q3). 
4Partly HPLC (n=190).
 580% between 49-61 years. 
6Determined using HPLC. 
7Range. 
8Not fasting. 
9Within 6 weeks after delivery   
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Folic acid fortification  
It has proven difficult to reach a food folate intake associated with a low risk 
of neural tube defects. Therefore the authorities in many countries aim to 
increase the population’s intake of folate or folic acid by e.g. information 
campaigns and fortification programmes, either voluntary or mandatory. 
Each method has its benefits and drawbacks, and an alternative might be 
good in one country but less good in another depending on initial folate 
status and prevalence of NTD.  
In the USA, Canada, Costa Rica and Chile, average folic acid intake has 
been increased by mandatory folic acid fortification of staple foods. 
Incidence of NTDs has decreased significantly (Mosley et al., 2009; Castilla 
et al., 2003), especially in areas with a high prevalence prior to fortification. 
For example, in Newfoundland, Canada, a 78% reduction (from 44/10 000) 
has been observed (Liu et al., 2004). Concerns have been raised that high 
intake of synthetic folic acid will result in unmetabolised folic acid in plasma 
and adverse health effects (Smith et al., 2008). For example, unmetabolised 
folic acid in fasting plasma samples was found in 75% of non-supplement 
users (n=705, Framingham Offspring Cohort) (Kalmbach et al., 2008). 
However, the implications of this are still under discussion (Smith et al., 
2008). 
Introduction of folic acid fortification in Sweden would bring about an 
estimated 25% reduction in abortions due to neural tube defects (current rate 
~80/year) and births with neural tube defects (current rate ~20-25/year) 
(SBU, 2007). However, due to concerns regarding the ambiguous role of 
folic acid in development of colorectal cancer, fortification has not been 
introduced (NFA, 2009b).  
1.4  Folate quantification in foods and clinical samples 
Four tons of spinach was used to isolate folate for the first time and hence 
the authors suggested the name folic acid from the Latin word folium, 
meaning leaf (Mitchell et al., 1941). Since then, a number of different 
methods for determination of folate content in clinical samples and foods 
have been developed (Figure 5), as reviewed by Quinlivan et al. (2006). The 
most suitable method depends on the type of sample and level of 
information needed, as well as time and financial restraints (Figure 5). 
Depending on method, folate data may vary. For example, folate data (food 
and clinical samples) obtained by HPLC methods are reported to be up to 
30% lower than those obtained by microbiological assays (Konings et al.,  
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2001; Finglas et al., 1996; Gregory et al., 1982) and ~30% higher than data 
on clinical samples obtained by radioassays (Pfeiffer et al., 2004).  
The great structural variations in folates (Gregory, 1996) complicate 
determination of folate content, since response (microbiological and 
radioassays) and sensitivity (HPLC methods) can vary between forms (Figure 
5). Another challenge during folate measurements is to avoid oxidative 
cleavage and preserve the reduction of the pteridin ring, which is commonly 
done by use of antioxidants, avoidance of UV-light and overlaying samples 
with gas. 
Folate concentrations were determined in this thesis using HPLC 
methods, in which the cellular structures of the sample are disrupted by 
homogenisation and heat extraction or by enzymatic degradation (e.g. the 
so-called trienzyme method), resulting in folates being released from the 
matrix by leakage (Gregory, 1996). Prior to quantification, purification is 
required, e.g. by solid phase extraction or affinity chromatography (Selhub, 
1989). Affinity chromatography is more sensitive and more selective due to 
the covalent binding of FBP to folates, which is more specific and stronger 
than e.g. the ion-binding in strong anion exchange columns (SPE method). 
However, the selectivity of the HPLC method depends mainly on the 
detector used and is superior for EC and MSMS followed by MS and FLD 
(Quinlivan et al., 2006; Bagley & Selhub, 2000).  
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Peak areas of individual folates are 
measured using various detectors
(FL, UV, MS, EC) after separation 
by differences in binding strength
to the stationary phase.
Radioactivity is measured after 
competive binding between sample
folates and a known amount of 
radiolabelled folate to folate 
binding protein (RBPA) or specific
antibodies (RIA).
Growth of microorganisms (e.g. L. 
rhamnosus) is dependent on 
exogenous folate. Measured
absorbance (growth) correlate to 
folate content in the sample.
Principle
HPLC (FL, UV, MS, MSMS, EC) Radioassay Microbiological assay
Expensive and high demands on 
extract purity. Limited number of 
folate standards commercially
available.
Variable affinity between different 
folate forms. Not suitable for foods
as binding is not selective for e.g. 
stereoisomers with vitamin activity.
Growth response may vary with 
assay pH and polyglutamic chain
length. Antifolates and antibacterial
drugs will affect results. 
Drawbacks
Quantification of individual folates. High sample throughput.  The only AOAC method. Sensitive.  Main advantage
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Figure 5. Overview of folate quantification methods summarised from Quinlivan et al. (2006). HPLC = high performance liquid chromatography;  
FL = fluorescence; UV = ultraviolet; MS = mass spectrometry; EC = electrochemical.   
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2  Objectives 
The overall objective of this thesis was to assess folate bioavailability. In vivo 
models to assess long-term effects of food folate on status and short-term 
absorption of fortificants were complemented with less expensive but well 
established  in vitro models (Table 5). The same test foods, analytical 
measurements and statistical evaluations were used whenever possible to 
enable comparison between study results (Table 5). Specific objectives were: 
 
•  To determine effects on folate status in women of an intervention 
involving two pieces of nutritional advice, a food (wholemeal bread) 
and a meal (breakfast). 
•  To determine folate bioavailability after ingestion of single doses of 
wholemeal bread fortified with either 5-CH3-H4folate or folic acid 
using a novel stable-isotope AUC/ileostomy model. 
•  To determine the bioavailability of folic acid ingested with 
wholemeal bread or as part of a complete breakfast meal using a 
novel stable-isotope AUC/ileostomy model. 
•  To determine in vitro bioaccessibility of endogenous folates from 
breads, a complete breakfast meal and orange juice using the 
dynamic TNO gastrointestinal model TIM. 
•  To assess effects of bread matrix on in vitro uptake and transport of 
the dominant food folate 5-CH3-H4folate using a novel stable 
isotope/Caco-2 cell model.  
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Table 5. Overview of trials included in thesis 
  In vivo  In vitro 
Model  Intervention   Plasma AUC/ileostomy   Gastrointestinal TIM  Caco-2 cells  
       
Paper  I II III&IV IV 
Objectives  Assess effects of two pieces 
of dietary advice on folate 
status in women. 
Assess absorbed and non-
absorbed fraction after 
ingestion of 
13C5-5-CH3- 
H4folate or 
13C5-folic acid (from 
fortified bread or meal).  
Assess bioaccessibility of 5-
CH3- H4folate and 10-HCO-
folic acid from orange juice, 
wholemeal and ryebran 
breads and a breakfast meal. 
Assess effects of wholemeal 
bread matrix on relative 
uptake of 
13C5-5-CH3- 
H4folate. 
Folate doses  0, 70, 125 µg/d  200 µg/portion  30-40 µg/gastric intake
1  0.2 µg/well (0.5 ml)
1 
Used test foods       
-breakfast
2  √  √   √ (IV)  - 
-wholemeal bread  √   √  √ (IV)  √ 
-orange juice  - - √ (III)  - 
Analysis of food samples   LC-MS
3&MA
4  LC-MS
3 HPLC-FLD
5 LC-MS
3 
Analysis of clinical or TIM 
& Caco-2 cells samples 
 
Radioassay
6 
 
SIDA/LC-MSMS
7 
 
HPLC-FLD
5  
 
LC-MS
3 
N  17 women/group (3)  8 ileostomists   2 independent trials/food  6 wells/test digests (2) 
Statistical analysis  Wilcoxon-Mann-Whitney 
rank-sum test  
Q-statistics   Q-statistics Wilcoxon-Mann-Whitney 
rank-sum test 
1Given amount of folate. 
2Contained wholemeal bread with liver-pâté, dairy product with cereals, orange juice and a kiwi. 
3In house folate determination 
using Agilent 1100 Series (Patring & Jastrebova, 2007). 
4At accredited laboratory (National Food Administration, Uppsala, Sweden).
 5In house folate 
determination using Agilent 1100 Series (Jastrebova et al., 2003). 
6At accredited laboratory (Quintiles AB, Uppsala, Sweden). 
7At Bioanalytik, 
Weihenstephan, Germany (Freisleben et al., 2003).  
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3  Material and methods 
3.1  Folate quantification 
Clinical samples were externally analysed using LC-MSMS or radioassays 
(Table 5), for details see papers I and II. In vitro and food (Table 6) samples 
were analysed using in-house HPLC methods. Test foods were analysed to 
determine doses and to account for batch and brand variations as well as 
potential storage losses (Table 6). 
Test foods and doses 
Test foods used in the in vivo and in vitro studies are listed in Table 6. The 
breakfast (Table 6, Figure 6) was composed with minor modifications 
according to Swedish Nutrition Recommendations Objectified (SNÖ) 
(Enghardt-Barbieri & Lindvall, 2005). (6S)-
13C5-5-CH3-H4folate (calcium 
salt) and 
13C5-folic acid, produced according to GLP/pharmaceutical 
standards, were purchased from Merck Eprova AG (Schaffhausen, 
Switzerland). The content of unlabelled folate in the standards was <1% as 
detected by LC-MS (Patring & Jastrebova, 2007). Wholemeal breads (Table 
6) were baked with the labelled standards (II, IV) at the Lantmännen test 
bakery, Järna, Sweden, as described in manuscript IV.   
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Table 6. Test foods used for in vivo and in vitro trials 
Test foods  Paper
1  Folate content checked for effect of: 
   Brand  Batch  Storage  (conditions) 
        
Breads (Lantmännen), stored at -20ºC         
- wholemeal (8% dietary fibre)   I  √  √  √ (-20ºC, 4 months) 
- wholemeal, fortified with labelled 
folate (test bakery) 
II,IV   √  
- wholemeal rye (8% dietary fibre)  I  √  √  √ (-20ºC, 4 months) 
- B3, made of B3-flour (test bakery)  IV  √    
- rye bran (test bakery)  IV  √    
Juices (JO-Bolaget), stored at 5-8ºC        
- orange juice diluted from 
concentrate  
III  √   √ (8ºC, 7 weeks) 
- orange juice ready to drink   I,II,III  √  √  √ (5ºC, 4 months) 
- apple juice ready to drink   I       
Breakfast cereals, stored at 5-8ºC (rye flakes) or ambient temperature (breakfast cereals)  
- rye flakes (test bakery, 
Lantmännen) 
I   √ (5ºC, 4 months) 
- breakfast cereals (17% fibre, Coop)  II,IV       
Other foods, stored at 5-8ºC         
- kiwi  I,IV    √  
- liver pâté (38% liver, ICA)  I    √  
- liver pâté (41% liver, Scan)  II,IV       
- fermented milk (3% fat, 
Norrrmejerier)  
II      
- fermented milk (0.5% fat, Arla)   IV       
1See Table 5. Food from Lantmännen (Järna, Sweden) and JO-Bolaget (Stockholm, Sweden) 
were obtained directly from the producers. The foods from Coop (Stockholm, Sweden); 
ICA (Solna, Sweden); Scan (Johanneshov, Sweden); Norrrmejerier (Umeå, Sweden) and Arla 
(Stockholm, Sweden) were purchased at local supermarkets.  
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Analytical methods 
In the intervention trial (I), the concentrations of serum folate, erythrocyte 
folate and plasma total homocysteine were externally analysed at a routine 
laboratory (Table 5) (Quintiles AB, Uppsala, Sweden) accredited by Swedac 
(Swedish Board for Accreditation and Conformity). Serum and erythrocyte 
folate concentrations were measured using Immunoassay Plus (BioRad, 
Sundbyberg, Sweden) and plasma total homocysteine using a CardiacMark 
1/2/3 (BioRad).  
In the ileostomy/plasma AUC trial (II), plasma and stomal effluents were 
externally analysed using a SIDA method with LC-MSMS detection 
modified from Freisleben et al. (2003). Analyses were carried out in 
duplicate with duplicate injection at Bioanalytik Weihenstephan, 
Technische Universität München, Germany. 
In the Caco-2 cell trial (IV), folates in the samples were stabilised with 
antioxidants (0.2% (w/v) ascorbate and 0.01% (v/v) 2,3-dimercapto-1-
propanol) directly after the experiment ended. Sample extracts were purified 
by centrifugation (10  000 rpm, 10 min) and strong anion exchange 
chromatography prior to LC-MS quantification as described in manuscript 
IV.  
TIM samples (III, IV), test foods and doses (I-IV) were analysed using 
methods based on the work of Patring & Jastrebova (2007), Jastrebova et al. 
(2003), Witthöft et al. (2003) and Johansson et al. (2002). In brief, all foods 
and in vitro TIM samples were homogenised and heat-extracted in phosphate 
buffer (pH 6.1) containing ascorbate and 2,3-dimercapto-1-propanol. For 
foods rich in starch, such as bread, thermostable α-amylase was added during 
heat extraction. After centrifugation the supernatant was incubated with rat 
serum (and α-amylase again for starchy foods) and thereafter purified on 
either SAX or affinity columns.  
Folate content was quantified using external calibration and an HPLC-
FLD/UV method (Jastrebova et al., 2003) or LC-MS method (Patring & 
Jastrebova, 2007). By using different wavelengths, quantification of 10-
HCO-folic acid in FLD was enabled (Pfeiffer et al., 1997b). The LC-MS 
method was adjusted to enable quantification of 10-HCO-H2folate, [6S]-
13C5-5-CH3-H4folate, [6S]-
13C5-5-HCO-H4folate and 
13C5-folic acid.  
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3.2  Intervention study with two pieces of nutritional advice (I) 
A randomised controlled parallel intervention study (Figure 6, I) was carried 
out. Folate status in healthy women was determined after intervention with 
two pieces of nutritional advice: a food recommendation (175 g fibre-rich 
bread, 70 µg folate (159 nmol)) and a complete meal (breakfast, 125 µg 
folate (283 nmol)) (Enghardt-Barbieri & Lindvall, 2005). The control group 
received apple juice (0 µg additional folate/day) (Figure 6).  
A total of 51 women who fulfilled the inclusion criteria (Figure 6), i.e. 
normal range of biochemical parameters (I), non-pregnant and non-nursing, 
were randomly assigned to the different groups.  
Folate status was assessed by concentrations of erythrocyte folate, serum 
folate and plasma total homocysteine at baseline, week 8 and week 12 of the 
trial (Figure 6). Fasting blood sampling was carried out at Good Food 
Practice, Uppsala, Sweden, and the study protocol was approved by the 
Regional Ethical Review Board in Uppsala, Sweden.  
Estimation of folate intake using FFQ 
To estimate changes in food folate intake during the trial, a 71-item Food 
Frequency Questionnaire (FFQ) was completed by volunteers at screening 
(3 month recall) and during the intervention trial (2 month recall) (Figure 
6). The software Dietist XP version 3.0 (Kost och näringsdata, Bromma, 
Sweden), using data from the Swedish food composition database (NFA, 
2006) and food industries, was used for calculations of folate intake.  
3.3  Plasma AUC/ileostomy study using stable isotope-labelled 
folate (II) 
A crossover trial with three independent study days separated by a wash-out 
period of 2-5 weeks was carried out. On study days, the ileostomy 
volunteers (n=8) were randomly assigned wholemeal bread fortified with 
~450 nmol (200 µg) of either (6S)-
13C5-5-CH3-H4folate (bread only) or 
13C5-
folic acid (bread only or as part of a complete breakfast containing 
feremented milk, breakfast cereals, orange juice and liver pâté). Post-dose 
plasma was collected for determination of plasma kinetics and stomal effluent 
for determination of the non-absorbed fraction of labelled folate.  
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Upsala Upsala Nya Tidning  Nya Tidning Sunday 25th of June 2006
Volunteers needed to an intervention trial. Inclusion critera: 
￿ healthy women aged 25-60 years,
￿ non-nursing, non-pregnant, not planning pregnancy and 
￿ not consuming folic acid supplements or fortified foods.
Interview General health
Dietary habits
Study purpose
Screening Folate  status 
Health check   
FFQ (n=67)
I N T E R V E N T I O N
Breakfast (n=17) Bread (n=17) Control (n=17)
I N T E R V E N T I O N
Orange juice (250 ml), 
wholemeal bread (70 g),
liver pateé (~15 g),
breakfast cereals (30 g),
kiwi (~60 g) and 
dairy product (own choice).
125 µg folate (283 nmol)
Wholemeal bread 
(175 g,  5 slices)
70 µg folate (159 nmol)
Apple juice 
250 ml) 
0 µg folate
Breakfast (n=17) Bread (n=17) Control (n=17)
Breakfast of own choice
Baseline Folate status 
(n=51)
Week 8 Folate status 
FFQ (n=51)
Week 12  Folate status 
Health check   
(n=51)
 
Figure 6. Outline of intervention trial.  
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During cannulation, a fasting baseline plasma sample was collected. Meals 
and sampling of plasma and stomal effluents were strictly standardised 
(Witthöft et al., 2003). Post-dose blood samples were collected at 20, 40, 60, 
90, 120, 180, 240, 360, 480, 600 and 720 minutes. Stomal effluent bags 
were changed every 2 hours during 12 h post-dose and by free choice 
between 12-24 h post-dose. This trial was carried out at the Centre for 
Clinical Research (KFC) in Umeå, Sweden and the study protocol was 
approved by the Regional Ethical Review Board in Uppsala, Sweden.  
3.4  Folate bioaccessibility assessed in the in vitro 
gastrointestinal model TIM (III, IV) 
In vitro studies were carried out with the dynamic, computer-controlled 
gastrointestinal model TIM (Minekus et al., 1995) to assess folate 
bioaccessibility (fraction of given folate available for absorption) from orange 
juice, two sorts of bread and a complete breakfast (Table 5). 
In brief, the so-called gastric intake, prepared by mixing the test food 
with a buffer solution, was placed in the gastric compartment of TIM on 
two separate days as described by Verwei et al. (2003). The gastric intake 
was mixed with electrolytes and enzymes during transport through the 
compartments of stomach, duodenum, jejunum and ileum (Minekus et al., 
1995). Bioaccessible fractions (from jejunum and ileum compartments) and 
non-bioaccessible fractions (from ileal deliveries) were collected for folate 
quantification during the 5 h experiment.  
3.5  Uptake of 
13C5-5-CH3-H4folate into Caco-2 cells (IV) 
Caco-2 cells were used to assess the effect of bread matrix on uptake and 
transport of stable isotope-labelled (6S)-
13C5-5-CH3-H4folate. Caco-2 cells, 
deriving from a human colon carcinoma cell line, differentiate spontaneously 
into cells resembling absorptive enterocytes (Hubatsch et al., 2007). Polarised 
Caco-2 cell monolayers are suitable for folate uptake studies since known 
folate transporters (Figure 3, PCFT, RFC, MRP) are expressed at the cells 
(Ashokkumar et al., 2007).  
Digests of wholemeal bread fortified with 
13C5-5-CH3-H4folate (Table 5) 
and a 
13C5-5-CH3-H4folate standard solution were prepared by enzymatic 
treatment in concentrations according to Salovaara et al. (Salovaara et al., 
2003), under simulated gastrointestinal conditions. The uptake and transport 
experiment was performed under sterile conditions using fully differentiated 
cells, at a pH of 6.3 at the luminal side and 7.4 at the basolateral side.   
  45 
In brief, the digests containing 0.4-0.5 µmol 
13C5-5-CH3-H4folate were 
added to the apical chambers and incubated for 60 min at 37°C in the dark 
under gentle shaking. Concentrations of labelled and unlabelled folate were 
measured in extracts from the lysed cells, the apical side and the basolateral 
side. Content of labelled folate polyglutamates in lysed cells was estimated by 
determination of folate content prior to and after deconjugation. 
3.6  Calculations and statistics 
The reliability coefficient (RC, intra class correlation) (Fleiss, 1986) shows 
the ratio of between subject variability to total variability. RC was estimated 
for each folate status parameter for volunteers in the control group in the 
intervention trial (I) as: 
RC = (BMS-WMS)/(BMS+(n-1)*WMS)       (1) 
where BMS is the between subject mean square error, WMS is within 
subject mean square error and n is number of replicates within subject. 
The AUC0→12 (median and range) of plasma data (II) was calculated using 
the trapezoidal method (Tozer & Rowland, 2006). Because 
13C5-5-CH3-
H4folate had not reached baseline concentrations (0 nmol) at the last blood 
sampling point (C720), AUC12→∞ was estimated by extrapolation from the last 
seven data points by log-linear regression analysis (Tozer & Rowland, 2006). 
Folate recovery (mass balance) of the plasma AUC/ileostomy model for the 
labelled folate forms was estimated as: 
R = (Cmax*V+Fnon-absorbed)/Fdose                       ( 2 )  
where Cmax is the highest measured concentration of labelled folate in plasma 
after given dose, V the distribution volume of folic acid (0.389 L/kg 
bodyweight as estimated (Loew et al., 1987)), Fnon-absorbed the labelled folate 
content in the stomal effluent (0-24 h) and Fdose the labelled folate content in 
dose.  
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Folate bioaccessibility as assessed by TIM gastrointestinal model (III,IV) was 
calculated using data from two independent TIM runs, each analysed in 
duplicate as: 
Bioaccessibility = Fdialysate/Ffood  portion                      (3) 
where Fdialysate and Ffood portion are folate content in dialysates (jejunal and ileal) and 
the TIM food portion, respectively.  
Folate recovery (mass balance) of the TIM model was calculated as: 
R = (Fdialysate+Fileal delivery+Fresidues)/Ffood portion                     ( 4 )  
where  Fileal delivery  and F residues are folate content in the ileal delivery (‘non-
absorbed’ fraction) and the residues (folate content in the model after the 
experiment) (Verwei et al., 2003), respectively.  
Folate uptake into Caco-2 cells (IV) was calculated using data on [6S]-
13C5-
5-CH3-H4folate from six wells as: 
Uptake = (Flysed Caco-2 cells+Fbasolateral)/Fdigest                      ( 5 )  
where Flysed Caco-2 cells, F basolateral and Fdigest are 
13C5-5-CH3-H4folate content in lysed 
Caco-2 cells, basolateral samples and digests, respectively.  
Folate transport into Caco-2 cells (IV) was calculated using data on 
13C5-5-
CH3-H4folate from six wells as: 
Transport = Fbasolateral/Fdigest                          ( 6 )  
Folate recovery (mass balance) of the Caco-2 cell model was calculated as:  
R = (Fapical+Flysed Caco-2 cells+Fbasolateral)/Fdigest                     ( 7 )  
where Fapical is 
13C5-5-CH3-H4folate content in apical samples.  
Analytical surrogate recovery (Thompson et al., 2002) was calculated as:  
R = (Fsample+analyte-Fsample)/Fanalyte                          ( 8 )   
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where Fsample+analyte is the folate content in the sample with surrogate analyte 
(spike) added, Fsample the content in the non-spiked sample and Fanalyte the 
added amount of surrogate analyte. 
Data on concentrations and content in clinical samples (plasma, erythrocyte 
and stomal effluents) were expressed as median and 1
st (Q1) and 3
d (Q3) 
quartile (I) or range (II). Folate contents in TIM and food samples were 
expressed as individual values (n=2, III) or mean±root mean square error or 
standard deviation (n>2, IV). Folate contents in Caco-2 cell samples (IV) 
were expressed as median and range. Since data were usually not normally 
distributed, non-parametric methods were used as standard.  
The Wilcoxon-Mann-Whitney rank-sum test was used to compare 
changes from baseline in active groups with the control group, i.e. 
intervention groups (I) and Caco-2 cell digests (IV) (Table 5). General linear 
model was used to assess BMS and WMS (equation 1). Q-statistics (Putt & 
Chinchilli, 2004; Öhrvik, 1998) for non-parametric analysis of high order 
cross-over trials was used to compare different study days in the plasma 
AUC/ileostomy study (II, Table 5). Kruskal Wallis test was used to compare 
doses in the plasma AUC/ileostomy trial. Minitab® ver 15.1.0.0 (Minitab 
Ltd., Coventry, UK) was used for these analyses. The Jonckheere-Terpstra 
test (StatXact-4 ver 4.0.1, Cytel Software Corporation, Cambridge, USA) 
was used to test for dose-response effects in the intervention trial (I). 
Associations (status- and biochemical parameters at screening of the 
intervention trial) were assessed by Spearman’s correlation coefficients (SAS 
ver 9.2, Cary, USA). A two-sided p<0.05 was regarded as statistically 
significant.   
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4  Results and discussion 
The objective of this thesis was to assess folate bioavailability using different 
in vivo and in vitro models but similar test foods and analytical methods. The 
main findings were: 
¾  Regular consumption of a breakfast following SNÖ recommendations (I) 
(Enghardt-Barbieri & Lindvall, 2005) improved folate status significantly. 
After the trial, more than 50% of volunteers had a status associated with 
the lowest risk of an NTD-affected pregnancy (compared with ~25% 
prior to the trial). 
¾  Regular consumption of 5 slices of wholemeal bread daily (I) maintained 
erythrocyte and serum folate concentrations and reduced plasma total 
homocysteine concentrations significantly.  
¾  Post-dose kinetics in peripheral plasma (II) differed significantly between 
folate forms. As labelled folate content in stomal effluents did not differ 
significantly between study days the difference could not be explained by 
differing bioavailability. 
¾  Bioavailability of 5-CH3-H4folate fortificant was as high as the 
bioavailability of folic acid fortificant from wholegrain bread (~90%), 
based on content of labelled folate in stomal effluent (II). 
¾  Bioavailability of folic acid fortificant from bread was similar after 
ingestion of folic acid with bread alone, and as part of a breakfast meal, 
based on content of labelled folate in stomal effluent (II). Post-dose 
kinetics in peripheral plasma was also not affected by the breakfast meal. 
¾  Foods rich in dietary fibre had some inhibitory effect (~25%) on folate 
bioaccessibility (III, IV) and uptake (IV) in vitro but not in vivo as less than 
10% of the labelled folate dose was found in stomal effluents (II).  
¾  Colon cells (Caco-2 cells) not only facilitated transport across the cell 
membranes but also retained folate within the cells by conjugation of a 
polyglutamate chain (IV).  
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4.1  Intervention study with two pieces of nutritional advice (I) 
After 12 weeks of regular consumption of either a complete breakfast 
(additional 125 µg folate (283 nmol)) or 5 slices of wholemeal bread daily 
(additional 70 µg folate (159 nmol)) (Figure 6), the effects of the 
intervention diets were observed as: 
 
¾  >20% increase in median erythrocyte folate concentrations for the 
breakfast group, which was significant compared with changes in the 
control group (-18%) (Table 7). 
¾   >20% reduction in plasma total homocysteine concentrations for both 
active groups (Table 7).  
In the control group (apple juice, 0 µg folate), folate status parameters were 
stable, although a trend (p=0.07) of decreasing erythrocyte folate 
concentrations was observed (Table 7), possibly reflecting a seasonal effect as 
observed by others (Hao et al., 2003; McKinley et al., 2001). 
Findings from trials using intervention diets with food folate are 
inconclusive, as some report no significant effects (Table 1a) while others 
report significant effects (Table 1b). Figures 7a-c show responses to 
intervention doses of trials in Table 1a and 1b and that in Paper I. Responses 
in erythrocyte and serum folate concentrations in (I) were in agreement with 
those in previous trials (Figure 7 a-b). However, the observed increase in 
serum folate of 2 nmol/L after consumption of the breakfast was not 
significant (p=0.06, Table 7). Therefore no conclusions can be drawn on the 
effect of the intervention on serum folate.  
Despite low food folate doses of ~100 µg/day in (I), plasma total 
homocysteine concentrations decreased significantly, with levels similar to 
responses observed in trials with intervention doses >400 µg food folate 
(Figure 7c). 
The pronounced decrease in homocysteine might partly be explained by 
our volunteers being women, who respond more efficiently to supplemental 
folic acid (Homocysteine Lowering Trialists, 2005). Except for Bogers et al. 
(Bogers et al., 2007), all other trials had volunteers of both genders or male 
only (Hannon-Fletcher et al., 2004). For homocysteine lowering a strongly 
significant dose-response effect (Table 7) was found, so folate was essential in 
the reduction of plasma total homocysteine concentrations. However, other 
food components involved in methylation of homocysteine (Figure 4), e.g. 
vitamin B12 (as provided by the liver pâté) and betaine (as provided by the 
wholemeal bread) might have contributed to the pronounced decrease.  
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Table 7. Concentrations of erythrocyte folate, serum folate and plasma total homocysteine at baseline, week 8 and week 12 of the intervention trial  
  Group  Control 0 µg/d (n=17)  Bread 70 µg/d (n=17)  Breakfast 125 µg/d (n=17)  Dose-response 
   median  Q1, Q3 median  Q1, Q3 vs.  control
1  median Q1, Q3 vs.  control
1  effect week 12
2 
                       
Ery-folate  Baseline  900  647, 1079  855  635, 992    805  742, 909 
   
(nmol/L)  Week 8  838  621, 1065  805  683, 998  p=0.58  856  740, 1112  p=0.095
   
  Week 12  735  641, 892  703  629, 839 p=0.78  990  763,  1058  p=0.019
  p=0.017
 
                
S-folate  Baseline  12  11, 15  12  9, 16    12  10, 16     
(nmol/L)  Week 8  13  11, 15  11  10, 15  p=1.00  14  12, 21  p=0.074   
  Week 12  12  9, 15  12  10, 16  p=0.23 13 12,  20  p=0.058 p=0.054 
                
tHcy Baseline  9.3 8.6,  11.1  9.1  7.9, 11.0    8.7  7.3, 10.3     
(µmol/L)  Week 8  9.9  9.0, 12.6  9.2  8.5, 11.6  p=0.35  9.0  7.3, 9.5  p=0.070   
  Week 12  9.6  7.6, 11.6  7.2  6.9, 8.5 p=0.076  6.7  5.6,  7.4 P<0.001  p<0.001 
Ery-folate = erythrocyte folate; S-folate = serum folate; tHcy = plasma total homocysteine. 
1Differences in changes from baseline between the control 
and each active group were tested for using Wilcoxon-Mann-Whitney rank-sum test. 
2Dose response effects at week 12 were tested for using 
Jonckheere-Terpstra test. 
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Figure 7 a-c. Response (%) in concentrations of a) erythrocyte folate, b) serum folate and c) plasma total homocysteine to intervention doses (µg/day) and 
Spearman’s correlation coefficients. Data are based on trials (n=6-10) listed in Table 1a and 1b and the Paper I. Responses (n=4) from the intervention 
doses in this trial (I) were marked with a ring  
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The health-related benefit of homocysteine lowering is under discussion. In 
a meta-analysis (12 clinical trials, n=16958) folic acid supplements were 
found to be ineffective in the prevention of cardiovascular disease among 
persons with a history of vascular diseases (Bazzano et al., 2006). 
Nonetheless, data from meta-analyses suggest a preventive effect of 
homocysteine lowering (>20%) on stroke (Saposnik et al., 2009; Wang et al., 
2007; Bazzano et al., 2006). 
Findings on folate bioavailability from different trials vary depending on 
the status parameter used for assessment (see section 1.2). In this trial (I) all 
status parameter seemed appropriate, based on reliability coefficients - 
estimated from the control group (Table 8) - within the range reported by 
others (0.65-0.97) (McKinley et al., 2001; Clarke et al., 1998; Garg et al., 
1997). 
Table 8. Evaluation of the folate status parameters in the intervention trial 
 Ery-folate  S-folate  tHcy 
      
Reliability coefficients (equation 1)  0.698  0.648  0.694 
Time (week) until significant response 
from a dose of 125 µg/day (n=17) 
>8 week  n.a.  8 week 
Correlations to the other parameters at screening (n=67)     
-to serum folate                                    0.770***  -  - 
-to plasma total homocysteine                   -0.266*  -0.281*  - 
-to serum vitamin B12                             0.130  0.111  -0.373** 
-to haemoglobin               0.326*  0.238  -0.151 
n.a. = non applicable. Spearman’s correlation coefficient, * p<0.05, ** p<0.01, *** 
p>0.001. 
To summarise, intervention with the breakfast meal improved folate status, 
whereas 5 slices of wholemeal bread maintained folate status. In an Irish 
study, the risk of an NTD-affected pregnancy was found to be eightfold 
higher for women having erythrocyte folate concentrations below ~340 
nmol/L compared with those having concentrations above ~900 nmol/L 
(p<0.001) (Daly et al., 1995). After regular consumption of the breakfast for 
12 weeks, the number of volunteers with erythrocyte folate concentrations 
>900 nmol/L more than doubled from 24% to 59% (I).   
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Folate intake estimations using FFQ (I) 
At screening of volunteers for the intervention study (Figure 6, I), median 
folate intake was estimated to be 279 µg/day (n=67), which is close to the 
recommended daily intake for adults (300 µg/day). However, folate intake 
varied significantly with age (Figure 8, p=0.04) and was only 244 µg/day for 
women of childbearing age (26-44 years). Only one volunteer (aged 26-44 
years) reached the recommended daily intake for this particular group (400 
µg/day). This is in agreement with data from the latest Swedish food intake 
survey (Becker & Pearson, 2003), but contradictory to findings from the 
Swedish Mammography Cohort (Larsson et al., 2004), where a higher folate 
intake was associated with lower age (Table 3).  
*
46-60 y (n=41) 26-44 y (n=26)
700
600
500
400
300
200
100
0
µ
g
/
d
a
y
 
Figure 8. Boxplots of estimated folate intake (µg/day) in women, grouped by age. Mean 
levels are marked by circles, the lines represent the Q1, Q2 and Q3.  
Folate from wholemeal bread, broccoli, dishes with beans, orange juice and 
liver pâté contributed nearly 50% of the median folate intake in volunteers at 
screening (n=67 women). Compared with national intake data (Becker & 
Pearson, 2003), the contribution from cereal products and beans was higher 
in the volunteers (I) while animal products contributed less (Figure 9).  
The intake estimation with the FFQ used in the intervention trial (I) was 
limited by several factors. Firstly, the study population (volunteers) was 
limited in size (n=67) and not representative of the general population. 
Secondly, the FFQ was not validated against another dietary assessment 
method or status parameters. Estimated folate intake did not correlate to 
measured concentrations of serum folate, erythrocyte folate or plasma total 
homocysteine (I) as reported for several validated FFQ (Brantsaeter et al., 
2008; Konstantinova et al., 2007; Owens et al., 2007; van de Rest et al.,  
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2007; Hickling et al., 2005; Pufulete et al., 2002). However, for the purpose 
of assessing changes in dietary folate intake during the intervention trial the 
FFQ (I) was considered sufficient. 
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Figure 9. Contribution (%) from food groups to folate intake. Comparison of data from 
Riksmaten 1997-1998, dietary recall, n= 215 women and men (Becker & Pearson, 2003) and 
from the screening of the intervention trial 2006 (I), 71-item FFQ, n=67 women, (median 
(Q1and Q3)) 
Folate intake and status of volunteers at screening for the intervention trial 
Estimated folate intake and folate status presented in this thesis are based on 
data from women screened to participate in the intervention trial (I). Hence 
neither data on intake nor status are representative for Sweden, but could 
possibly reflect a health-interested population of women. Some features of 
the women (n=67) were: 
¾  None of the women was folate-deficient, defined as serum folate 
concentrations below 7 nmol/L and erythrocyte folate concentrations 
below 363 nmol/L (Herbert & Das, 1994). 
¾  Although volunteers were instructed to avoid folic acid-fortified foods 
and supplements for two months prior to the screening, erythrocyte 
folate concentrations were about 30% higher than for US women in the 
post-fortification era (McDowell et al., 2008). 
¾  30% of the women had a folate status associated with the lowest risk of 
NTD (>900 nmol/L) (Table 9) (Daly et al., 1995). 
¾  For women of childbearing age there was a large gap of 40% between 
estimated (240 µg/day) (Figure 8) and recommended (400 µg/day) 
(NNR, 2005) folate intake.  
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In Table 9, concentrations of erythrocyte folate and serum folate of women 
in the Uppsala area at screening (Öhrvik et al., 2009; Johansson et al., 2002) 
are ranged according to estimated risk of neural tube defects as determined 
by Daly et al. (1995).  
About 70% of the women in both studies had already at screening 
erythrocyte folate concentrations associated with a low risk (0.15%) of an 
NTD-affected birth (and pregnancy). After the intervention trial median 
erythrocyte folate concentrations (Table 7) were >900 nmol/L for women 
in the breakfast group. Thus demonstrating that only minor additional folate 
intake (~125 µg/day), as achieved by following SNÖ recommendations 
(Enghardt-Barbieri & Lindvall, 2005), is required to reach erythrocyte folate 
concentrations associated with the lowest NTD risk (Table 9) (Daly et al., 
1995). 
Table 9. Folate status of women in Uppsala, grouped by estimated NTD risk at screening 
nmol/L  Risk of NTD/1000 births
1  2006 (n=67)
2   2001 (n=33)
3  
Erythrocyte folate concentrations  % % 
0-339 6.6  0  0 
340-452   3.2  6  0 
453-679   2.3  27  30 
680-905   1.6  37  30 
>906   0.8  30  40 
Serum folate concentrations    
0-4.4 3.7  0  0 
4.5-6.7 2.6  1  0 
6.8-11.2 1.9  24  15 
11.3-15.8 1.5  45 21 
>15.9 0.9  30  64 
1Estimated in Ireland (where termination of pregnancies is prohibited) according to Daly et al. 
(1995). 
2Öhrvik et al. (2009). 
3With kind permission of Johansson et al. (2002).  
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4.2  Plasma AUC/ileostomy study using stable isotope-labelled 
folate (II) 
In this randomised cross-over study, the plasma kinetics of labelled folate 
were studied 12 hours after ingestion of either [6S]-
13C5-5-CH3-H4folate or 
13C5-folic acid. Independent of the folate form ingested, a plasma curve with 
13C5-5-CH3-H4folate was obtained (Figure 10). No other labelled folate 
forms were detected. Bioconversion of a dose of 450 nmol 
13C5-folic acid 
into 
13C5-5-CH3-H4folate (Figure 3) thereby appeared complete.  
Median plasma AUC0→∞ (equation 2) was 89 (48-111) h·nmol/L after 
ingestion of 
13C5-5-CH3-H4folate-fortified wholemeal bread. This was nearly 
twice the estimated AUC0→∞ after ingestion of 
13C5-folic acid-fortified 
wholemeal bread, which was 50 (38-81) h·nmol/L (Table 10, Figure 10). 
Tmax and Cmax also varied significantly depending on folate form in the dose 
(Table 10, Figure 10). Consumption of the 
13C5-folic acid-fortified 
wholemeal bread with a breakfast meal instead of bread alone resulted in 
similar median plasma AUC0→∞, which was 47 (26-119) h·nmol/L, Tmax and 
Cmax (Table 10, Figure 10).  
 
Table 10. Kinetic parameters of 
13C5-5-CH3-H4folate in plasma after single test doses in random order. 
Median (range) of 8 ileostomists 
 Bread  fortified 
with 
13C5-5-CH3-
H4folate 
Bread fortified 
with 
13C5-folic 
acid 
Bread fortified with 
13C5-folic acid as part 
of complete 
breakfast 
p
 
        
(
13C5)-dose (nmol)  464 (450-467)  451 (448-472)  462 (448-471)  0.61
1 
(
13C5)-AUC0→∞ 
(h·nmol/L)
2 
0.20 (0.10-0.24)  0.11 (0.08-0.18) 0.10  (0.05-0.25)  0.0053
3 
(
13C5)-Cmax (nmol/L)  10.6 (6.3-16.5)  3.1 (1.7-4.5)  3.3 (2.1-5.7)  <0.001
3 
(
13C5)-Tmax (min)  40 (40-90)  150 (90-240)  240 (120-240)  0.003
3 
1 Differences in test doses were controlled using Kruskal Wallis test. 
 2 Dose-normalised 
13C5-
AUC0→∞ (AUC/dose). 
3Differences in response to test doses were tested using Q-statistics for 
non-parametric analysis of high order cross-over trials (Putt & Chinchilli, 2004; Öhrvik, 
1998). 
13C5-AUC12→∞ was estimated by extrapolation using log-linear regression analysis of the 
plasma concentrations in the elimination phase (Tozer & Rowland, 2006) (section 3.6). 
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Figure 10. Individual plasma curves of 
13C5-5-CH3-H4 folate after single test doses of 
13C5-5-CH3-H4 folate-fortified bread (circle), 
13C5-folic acid- fortified 
bread (unfilled triangle) and a breakfast meal containing 
13C5-folic acid-fortified bread (filled triangle).    
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Discrepancies in post-dose kinetics between doses of 
13C5-5-CH3-H4folate 
and 
13C5-folic acid (Table 10, Figure 10) might partly be explained by a less 
precise estimate of plasma AUCs after ingestion of 
13C5-folic acid doses. At 
Tmax after ingestion of folic acid doses, sampling interval was less frequent 
(every 60 min, Figure 10) than after ingestion of 
13C5-5-CH3-H4folate (every 
20 min, Figure 10). Hence, Cmax and AUC0→∞
  might have been 
underestimated after ingestion of 
13C5-folic acid. In addition, the delayed Tmax 
also resulted in a less distinct curve shape (Figure 10) resulting in an 
AUC0→12 of only about 55% of the total AUC0→∞
 after extrapolation.  
In the stomal effluents collected during 24 h post-dose, the ingested 
labelled forms (
13C5-5-CH3-H4folate and 
13C5-folic acid) and unlabelled 
H4folate, 5-CH3-H4folate and 10-HCO-folic acid were found (Figure 10). 
The content of labelled folate in stomal effluent varied from 2-9% of the 
given dose (Table 11) and did not differ significantly (p=0.15) with respect 
to folate form in dose or how the dose was ingested (with bread only or as 
part of a breakfast). 
Table 11. Content of folate (nmol) in stomal effluents collected during 24 h after oral doses of ~450 
nmol folate. Median (range) of 8 ileostomists 
 Bread  fortified 
with [6S]-
13C5-5-
CH3-H4folate 
Bread fortified 
with 
13C5-folic 
acid 
Bread fortified with 
13C5-folic acid as part 
of a breakfast 
      
(
13C5)-5-CH3-H4folate
  13.1 (9.8-31.2)  0.5 (0.1-1.0)  0.7 (0-5.0) 
(
13C5)-folic acid  not detected  24.5 (8.7-32.1)  25.3 (7.7-37.3) 
Relative (
13C5)-labelled folate 
content as % of dose
1 
2.8 (2.1-6.7)  5.4 (1.9-7.2)  5.6 (1.7-9.0) 
Unlabelled folate content
1,2  
(nmol) 
99 (52-178)  106 (43-148)  103 (46-166) 
1No significant differences in non-absorbed labelled folate were found between the test meals 
using Q-statistics for non-parametric analysis of high order cross-over trials (Putt & 
Chinchilli, 2004; Öhrvik, 1998). 
2Unlabelled folate content in stomal effluents collected 
during 12 h post-dose only (stomal collection from 12-24 h post-dose was not standardised). 
Unlabelled folate intake during 0-12 h was 140 nmol for study days with bread and 380 nmol 
for the study day with the breakfast meal, including folates from thest foods and other meals.  
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A minimal fraction of the stomal effluent after ingestion of 
13C5-folic acid 
was 
13C5-5-CH3-H4folate (about 0.6 nmol/24 h, Table 11). By LC-MS 
analysis (II) it was confirmed that the 
13C5-folic acid-fortified bread 
contained no 
13C5-5-CH3-H4folate. Therefore it can be hypothesised that 
13C5-5-CH3-H4folate detected in stomal effluents originated from 
bioconverted 
13C5-folic acid. Bioconverted 
13C5-folic acid might have ended 
up in the stomal effluent after release from either lysed enterocytes or newly 
produced bile in the gastrointestinal tract. According to previous estimates, 
at least 10% of daily folate intake is secreted into bile (Gregory & Quinlivan, 
2002) and nearly completely (96%) reabsorbed in the gastrointestinal tract 
(Lin et al., 2004). In the plasma AUC/ileostomy model low fat diets were 
used on study days (12 h post-dose), which minimised bile flow and thereby 
folate excretion into the gastrointestinal tract.  
Volunteers’ total folate intake of labelled and unlabelled folate by test 
foods and other meals on the study days (t=0-12h) was ~590 (bread days) 
and ~830 nmol (breakfast days) of which 60-80% (~450 nmol) was labelled. 
Median labelled folate content in stomal effluents was only 17% (5-36) 
(Table 11). Hence, it can be assumed that the majority of folates in stomal 
effluents do not originate from non-absorbed recent dietary intake but 
possibly from lysed enterocytes and gastrointestinal secretions such as bile 
(Gregory & Quinlivan, 2002).  
Stomal effluents collected during 12 h post-dose contained 103 (43-178) 
nmol unlabelled folate (Figure 11) and the level did not differ significantly 
between study days (Table 11) (p=0.53).  
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Figure 11. Content (nmol) of unlabelled folates in stomal effluents during 0-12 h and 12-24 h 
post-dose. Median content (range) is based on data from 8 volunteers on three independent 
test days (n=24), each analysed as duplicates. Volunteers’ diet during 12-24 h post-dose was 
not standardised  
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Differences in absorption kinetics between reduced folates and folic acid 
have been reported by others (Wright et al., 2005; Wright et al., 2003; 
Konings et al., 2002). Wright et al. (2005) postulated that bioconversion of 
folic acid occurs in the liver and not in the enterocytes as generally accepted. 
Hence a greater hepatic retention of folic acid, caused by liver enzymes 
having greater affinity to folic acid than reduced folates, would explain the 
difference in appearance in peripheral plasma (Wright et al., 2005). Wright et 
al. (2005) estimated hepatic retention of absorbed folates in volunteers 
without presaturation of body stores. For absorbed 
13C5-folic acid hepatic 
retention was estimated as high as 73%, which was significantly higher than 
after ingestion of 
13C5-5-HCO-H4folate (58%) and intrinsically labelled 
spinach folate (52%) (Wright et al., 2005). 
Variable affinity of folate transporters – thereby variable mobility – might 
contribute to different kinetics in peripheral plasma in vivo. For example, the 
affinity of PCFT (Figure 3), which is assumed to facilitate the main 
absorption of folates in the small intestine, is threefold lower to folic acid 
than to reduced folates (at pH 6.5) (Qiu et al., 2006). Within the cells, folic 
acid might be more retained, since the cellular efflux facilitated by multidrug 
associated proteins (MRP, Figure 3) is two- to 10-fold higher for reduced 
folates than folic acid (Assaraf, 2006). Furthermore, transport via systemic 
circulation might differ, e.g. affinity of PCFT to folic acid is negligible in 
plasma (pH 7.4), whereas reduced folates may be efficiently transported (Qiu 
et al., 2006). 
The discussion above is hypothetical but could partly explain the findings 
of Wright et al. (2005; 2003) and findings of the current trial (II). However, 
this needs to be further studied using isolated supplements.   
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4.3  Folate bioaccessibility assessed in the in vitro 
gastrointestinal model TIM (III, IV) 
The in vitro TIM experiments revealed high folate bioaccessibility (equation 
3), 75% in bread (IV), 95% in the breakfast (IV) and 100% in the orange 
juice (III) (Figure 12). Hence, folates appeared to be both released from the 
food matrix and stable during passage through the simulated gastrointestinal 
tract. Bioaccessibility of breakfast folate was similar to that of orange juice 
folate (Figure 12) and orange juice contributed with 60% of the folate 
content in the breakfast. 
Bioaccessibility data were in agreement with previous TIM data for   
beverages (80-100%) and solid foods (75-85%) (Verwei, 2004; Verwei et al., 
2004; Arkbåge et al., 2003; Verwei et al., 2003). 
0
20
40
60
80
100
Orange
juice
Breakfast Ryebran
bread 
B3-bread
B
i
o
a
c
c
e
s
s
i
b
l
e
 
f
o
l
a
t
e
 
(
%
 
o
f
 
i
n
t
a
k
e
)
 
Figure 12. Bioaccessible folate as percentage of folate content in test foods (for details see 
Table 6). Mean ± root mean square error of two TIM trials (each analysed in duplicate, n=4)  
As discussed in section 1.2, several matrix-related factors may inhibit folate 
absorption. For example Tamura et al. (1973) found incomplete in vivo 
availability of folates in orange juice, probably caused by reduced 
deconjugation of folate-polyglutamates (Wei & Gregory, 1998). Data from 
the TIM trial with orange juice indicate that folate bioaccessibility was 
complete (Figure 12).  
The lower folate bioaccessibility from wholemeal breads (~75%) 
compared with orange juice (100%) (Figure 12) is probably due to dietary  
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fibres, which are suggested to inhibit folate absorption e.g. by entrapment 
(Melse-Boonstra et al., 2004a). Data on the effect of dietary fibre on folat 
bioaccessibility as assessed in the TIM model are sparse. However, Verwei 
(2004) report a folate bioaccessibility of 87% in hard bread (knäckebröd).  
The TIM experiments indicated good folate in vitro bioavailability from 
the breakfast (Figure 12). This was also confirmed by findings in the 
intervention trial, where the breakfast significantly improved folate status of 
the women (I). 
To summarise, folate bioaccessibility was high for all tested foods (Table 
5). Whereas in vitro bioaccessibility for folates from the wholemeal bread rich 
in dietary fibre tended to be at the lower range at 75%, a 3-month 
intervention with this type of bread could maintain volunteers’ good folate 
status. 
4.4  Uptake of 
13C5-5-CH3-H4folate into Caco-2 cells (IV) 
Uptake into Caco-2 cells (equation 5, section 3.6) and transport across 
monolayers (equation 6) was determined for 
13C5-5-CH3-H4folate. Uptake of 
labelled folate
  fortificant from the bread matrix digest (15±2%) was 
significantly lower than from the folate standard digest (22±3%) (p<0.05). 
However, transport across the cells (6±1% & 6±2%) did not differ 
significantly (p=0.32). 
Folates are polyglutamylated to increase retention within the cells (Figure 
3, H). The 15% increase in 
13C5-5-CH3-H4folate content in lysed cells after 
incubation with rat serum (deconjugation) indicates that cellular storage of 
labelled folate occurred already within the one-hour experiment.  
Others have mainly studied uptake mechanisms of the oxidised folate 
form folic acid into Caco-2 cells (Subramanian et al., 2008; Ashokkumar et 
al., 2007; Mason et al., 1990) or effects of dietary compounds on folic acid 
uptake (Lemos et al., 2004; Verwei et al., 2005). However, Verwei et al. 
(2005) also report uptake and transport of the reduced folate form 5-CH3-
H4folate into Caco-2 cells. Measured uptake of radiolabelled 5-CH3-H4folate 
(3%) in that trial (Verwei et al., 2005) was sevenfold lower than in the 
current trial (22%, IV). Verwei et al. (2005) carried out the experiment at a 
higher pH of 7.4, where affinity of PCFT to folates is much lower than at 
pH values around 6 (Mason et al., 1990; Russell et al., 1979). Furthermore, 
Verwei et al. (2005) used a racemic (6R/6S) 5-CH3-H4folate mixture and it 
is possible that uptake of the diastereoisomer without biological activity (6R, 
Figure 1) is lower.  
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Recently, Aufreiter et al., (2009) reported in vivo absorption of folates in 
the human colon. After caecal infusion of [6S]-
13C5-5-HCO-H4folate they 
found 
13C5-5-CH3-H4folate and minor amounts of 
13C5-5-HCO-H4folate in 
peripheral plasma, indicating a conversion of 
13C5-5-HCO-H4folate in the 
colon- and/or livercells. According to Wright et al. (2005; 2003) conversion 
occurs in the liver instead of the gastrointestinal tract as is generally accepted. 
Using the Caco-2 cell/stable isotope model (IV) folate conversion in colon 
cells can be studied.  
To summarise, data from the Caco-2 cell trial showed that dietary fibre 
had an inhibitory effect on uptake of 5-CH3-H4folate in colon cells and that 
some 5-CH3-H4folate was retained as folate polyglutamate within the cells. 
4.5  Folate quantification 
Quantification of folate content in foods and clinical samples is challenging, 
mainly due to the low initial concentrations in the samples and interfering 
matrix compounds. For HPLC methods the sensitivity of the instrument can 
also be limiting.  
Folate content in test foods and clinical samples 
Examples of folate content and dominant forms in test foods are shown in 
Table 12. Discrepancies to reference values (national food composition 
database or determined at an accredited laboratory) can partly be explained 
by methodological differences. Folate data in food composition tables are 
usually expressed as total folate content from microbiological assay. Results 
from HPLC are usually expressed as sum of analysed individual folates - 
often only 2-6 forms (Jastrebova et al., 2003; Pfeiffer et al., 1997b) – and are 
therefore commonly lower than results from microbiological assays (Konings 
et al., 2001; Gregory et al., 1982). This is probably why the folate content of 
the certified reference material CRM 121 determined with the in-house 
method was 74% of the reference value determined using microbiological 
assay (Table 12).  
Although the microbiological assay is considered the golden standard, it 
has some limitations (Figure 5). Folate content in a breakfast extract (Table 
12) as assessed by microbiological assay and an in-house LC-MS method 
(Patring & Jastrebova, 2007) indicates that H4folate was lost during the 
sample pretreatment for the microbiological assay. This was probably due to 
the total incubation time, which was sevenfold longer (~22h) for the 
microbiological assay used at the accrediated laboratory. The longer 
incubation most likely also explain the substantial increase of oxidised folates  
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(10-HCO-folic acid), which was observed in this sample (Table 12). Hence, 
microbiological assays might be less appropriate for analysis of foods rich in 
H4folate, such as liver pâté, as demonstrated by the twice as high folate 
content in liver pâté analysed by LC-MS (Table 12).  
Table 12. Folate content as mean and SD (µg/100g) in test foods used for in vivo and in vitro 
trials measured by HPLC
1 
 Trial  n
2 H 4folate 5-CH3-  5-HCO-  10-HCO-  Sum as   Ref.
  
         H4folate H4folate  folic acid  folic acid
   
Wholemeal 
bread 
I,II,IV 6  traces  7±1  18±6  13±3
  45±4
3 42±3
4 
Wholemeal rye 
bread 
I 2  1±1  6±0 19±4  3±0
  27±0
5 40±4
4 
B3-bread IV  3  traces  16±1  16±2  14±4  43±4
6  16-44
7 
Rye bran bread  IV  3  traces  4±1  19±4  18±1  39±4  16-44
7 
Orange juice,   III  5  traces  25±2  nd  nd  24±2
  15-30
7 
from concentrate           
  
Orange juice, 
ready to drink 
I,III 4 traces  21±4  nd  nd  20±4
  15-30
7 
Rye bran cereal  I  2  traces  5±0  7±0  6±0  54±2
8 56±2
4 
Kiwi I,II,IV  4  1±1  22±2  nd  traces
  22±2 42
7 
Liver pâté  I,II,IV  4   77±4  20±4  nd  nd
  96±1 36
7 
Breakfast I,II,IV  4  6±0  19±0  8±1  2±0  33±1
 
Breakfast
9 I,II,IV  2  nd  14±1  7±1  14±2  35±1
  29±1
4 
CRM whole-
meal flour 121 
 3  4±1  8±1 17±0 9±1  38±1  50±7
10 
Ref = reference value; Traces = peak areas below limit of quantification (0.3-4 ng/mL); nd 
= not detected. 
1Patring & Jastrebova, 2007; Jastrebova et al., 2003; Witthöft et al., 2003; 
Johansson et al., 2002. 
2Analytical n (as example from one batch of each food and meal). 
310-
HCO-H2folate (9±2 µg/100g) included into sum of folate. 
4Data presented as mean±SD 
were analysed using accredited microbiological assay (National Food Administration). 
510-
HCO-H2folate was not included into sum of folate due to coeluting peaks. 
610-HCO-
H2folate (8±2 µg/100g) included into sum of folate. 
7Range (or individual values) of food 
composition database values for similar products (NFA, 2009a). 
810-HCO-H2folate (39±1 
µg/100g) included into sum of folate. 
9LC-MS quantification of the sample extract prepared 
for microbiological assay at accredited laboratory of National Food Administration (Uppsala, 
Sweden). 
10Certified reference value by microbiological assay (n=15, replicates 73). 
It is important when carrying out intervention trials to have control on 
effects from storage and batch variation on folate content in test foods (Table 
6). Due to the duration of the intervention trial (I), different batches of kiwi 
and liver pâté had to be used. Furthermore, wholemeal breads, rye bran 
cereal, orange juice and apple juice had to be stored ~4 months at 5ºC or - 
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20ºC. Therefore, variations in folate content due to storage and differences 
in brands and batches were checked (Table 6).  
No crucial variations in folate content of test foods due to use of different 
batches or storage was found. For wholemeal bread folate content was 
similar between batches (I,II) (Figure 13) and no losses were found during 
the four months of storage at -20°C (I) (data not shown).  
Folate content in orange juice was stable during storage in the 
intervention trial (4 months, 5°C). No difference in folate content between 
orange juice brands (Table 12) and batches (Figure 13) were found. Folate 
content in kiwi and liver pâté (purchased at three occasions in October, 
December and February) varied by almost 20% between batches (Figure 13). 
However, as the contribution of these foods to total folate intake from the 
breakfast was below 25%, the batch variations (~20%) did not affect the 
intervention doses substantially. This is demonstrated by a lower batch than 
analytical variation for the breakfast meal (intra-assay CV, Figure 13).  
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Figure 13. Batch variation (staples, n=2-3) and analytical variation (----, based on intra-assay 
CV, n=3-4) in breakfast ingredients and a composite sample. OJ = orange juice  
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Quality parameters of analytical methods 
Data on folate content in foods were considered acceptable if the precision 
under repeatability conditions (intra-assay CV) was below 10% for the sum 
of folates (Table 13). For individual forms with a low content in foods, a CV 
of up to 20% was accepted (Table 13). Due to the low folate concentrations 
in some of the plasma and stomal effluent samples an intra-assay CV of up to 
25% (n=4) was accepted. 
Table 13. Quality parameters of the methods used  
 HPLC-FLD/MS  SIDA-LC-MSMS 
Lowest quantifiable amount
  0.4-11.2 µg/100g
1  1 nmol/L (plasma)
2,  
64 pmol/g (stom effl)
2 
Intra-assay CV % (n=4)  <10 (1-20)
3  <5
 
Inter-assay CV % (n=4)  <20 (2-25)
3  <20
 
Recovery % (equation 8)  97±10 (77-127)
3  Not applicable
 
Stom effl = stomal effluent. 
1Lowest quantifiable amount expressed in µg/100g (accounting 
for dilution during sample preparation). Calibration levels (at least 6) that differed <20% from 
the theoretical value of the calibration curve (with R>0.999) were used for the calibration. 
2Limit of detection. 
3Range for individual folate forms.  
4.6  Suitability of folate bioavailability models 
Main findings from the in vivo and in vitro models are summarised for 
comparison (Table 14). Choice of method to assess bioavailability depends 
on the aim.  
If the aim is to examine physiological effects long-term intervention trials 
assessing more than one status parameter are preferable. The dietary 
intervention (I) affected two of three status parameters, erythrocyte folate 
and homocysteine concentrations, but not serum folate concentrations. As a 
similar RC was estimated for all parameters (Table 8), the lack of response in 
serum folate concentrations is probably due to fastened serum folate being 
less sensitive to minor changes in food folate intake.  
Many intervention trials have assessed the effect of food folate on folate 
status and results are inconclusive (Table 1a and 1b). However, several of 
these trials were carried out using unphysiologically high doses and total 
folate intake by interventions were often far above recommendations 
(Fenech et al., 2005; Venn et al., 2002; Riddell et al., 2000). More trials with 
intervention diets likely to be consumed by the general population and in 
physiological range would possibly result in more consistent data on folate 
bioavailability.   
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For the plasma AUC/ileostomy model (II), the TIM model (III, IV) and 
the Caco-2 cell model (IV), recoveries from given amounts of folate were 
calculated. A recovery different from 100% (Table 14) may indicate 
incomplete sampling, losses during storage and sample preparation and 
analytical errors. It could be questioned to calculate recovery for the plasma 
AUC/ileostomy model (equation 2, section 3.6), as the estimation of 
absorbed folate using Cmax*V in peripheral plasma is a rough measure (Tozer 
& Rowland, 2006). Furthermore, the low recovery for folic acid (<30%, 
Table 14) can be explained by physiological reasons other than above named 
and supports the hypothesis of Wright et al. (2005; 2003) regarding liver 
retention.  
The plasma AUC/ileostomy model (II) was used to assess food matrix 
effects and differences in absorption kinetics between oxidised and reduced 
folates (Table 10). The model could also be used to prove enterohepatic 
circulation. Post-dose secretion from oral doses of labelled folate (e.g. 
13C5-5-
HCO-H4folate and 
13C5-folic acid) into bile is reflected by 
13C5-5-CH3-
H4folate content in stomal effluent. It could be hypothesised that 
13C5-5-
CH3-H4folate content in bile differs when minimising or stimulating bile 
secretion and variation of biliary folate excretion could be assessed from 
stomal folate content. 
For the TIM model (III,IV) recovery was considered satisfactory and was 
confirming findings by others (Verwei, 2004), indicating a well functioning 
model. Furthermore the TIM model is a rather cheap and easy tool to study 
the effects of food matrix on folate bioaccessibility. Other purposes for 
which the model can be used are systematic assessments of effects of food 
processing on folate bioaccessibility. 
The novel Caco-2 cell/stable isotope model (IV) was used to assess 
matrix effects from the wholemeal bread on cellular folate uptake and 
transport. The model could further be used to study whether methylation 
and reduction of folates could occur in colon cells by application of e.g. 
13C5-
5-HCO-H4folate and 
13C5-folic acid. Furthermore, this model could be used 
to detect whether rate of transport across, and storage within, the colon cells 
varies between reduced folate forms and folic acid. 
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Table 14. Summary of results and evaluation of the bioavailability models used in this thesis 
  In vivo  In vitro 
Model  Long-term intervention  Plasma AUC/ileostomy  Gastrointestinal TIM  Caco-2 cells 
Paper  I II  III&IV IV 
Main result  Low doses of food folate (125 
µg/day) significantly improved 
folate status to a nutritionally 
relevant level according to 
Daly et al. (1995). 
Plasma kinetics differed 
significantly between 
13C5-5-CH3-
H4folate and 
13C5-folic acid. 
Bioavailabilities of both folates 
were similar from different 
matrices and around 90%. 
Folate bioaccessibility from 
wholemeal bread was significantly 
lower than from orange juice. 
Bioaccessibility of folates from a 
breakfast and orange juice was high 
(>90%). 
Wholemeal bread matrix 
significantly reduced relative 
uptake of 
13C5-5-CH3-
H4folate into Caco-2 cells. 
Minimum 
effective dose 
70 µg/d (tHcy) 
125 µg/d (ery-Folate) 
200 µg (labelled folate)  >15 µg of each folate form of 
interest /100 g food 
>0.2 µg/well 
Model 
recovery
1  
Not applicable  82±25% (5-CH3-H4folate, n=8) 
28±9% (folic acid, n=16) 
93±13% (n=4)  93±10% (n=11) 
Advantages of 
the model 
Physiological effects on folate 
status can be studied. 
The combination of methods 
strengthens results. 
Full compliance and lack of biological variation results in 
reproducible results from few experiments. No ethical limitations. 
  Results may be applicable to 
specific populations. 
Use of stable isotopes improves 
sensitivity and specificity. 
  Information on mechanisms 
can be assessed. 
Limitations of 
the model 
Unless a dose-response effect is 
established, effects as result 
from other food components 
cannot be excluded. 
Problems with compliance. 
Data from ileostomists can only 
with care be applied to the 
general population. 
 
Findings need to be  
confirmed in vivo. 
This cell line originates from 
one individual. 
Tumourgenic cell line. 
 
1Equations 2, 4 and 7 (section 3.6).   
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5  Concluding remarks and future 
perspectives 
Epidemiological studies (Table 3) confirm that intake of folate in Sweden is 
among the lowest in Europe (Dhonukshe-Rutten et al., 2009; Becker & 
Pearson, 2003). On the other hand, the prevalence of folate deficiency and 
neural tube defects is no higher in Sweden than in other Western countries 
(SBU, 2007; Busby et al., 2005), including those with mandatory folic acid 
fortification (McDowell et al., 2008). Obviously factors other than daily 
folate intake, which comprises only up to 4% of the folate body pool (Lin et 
al., 2004; Gregory et al., 2001; Herbert, 1987) affect folate status.  
Folate homeostasis is known to be well regulated, e.g. deficiency increases 
the expression of folate transporters in the small intestine and the proportion 
of protein-bound folates in plasma, resulting in increased absorption and 
reduced excretion (Zhao et al., 2009). Moreover, the colon microflora may 
affect folate status positively (Camilo et al., 1996). As shown by several 
intervention trials, folate intake (Table 1a and 1b) and folate bioavailability 
(Hannon-Fletcher et al., 2004; Cuskelly et al., 1996) both affect folate status. 
However,  in vivo data on factors affecting folate status are limited. E.g. 
findings on the bioavailability of folates are partly contradictory and data on 
the human colon microflora scarce (Aufreiter et al., 2009; Kim et al., 2004). 
The bioavailability of supplemental folic acid is considered superior to 
that of reduced folates (Sauberlich et al., 1987). In addition, folic acid is the 
most stable and cheapest form to synthesise and is therefore used for 
fortification purposes. However, a high intake of folic acid has been 
associated not only with health benefits but also adverse health effects, e.g. 
colorectal cancer as reviewed by Smith et al. (2008). Although these health 
effects are not well documented, they emphasise the need to understand the 
metabolism and bioavailability of both food folate and synthetic folic acid.   
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In short-term trials without presaturation of body stores, a difference in 
post-dose plasma kinetics has been observed between reduced folates 
deriving from foods, and supplemental folic acid (Wright et al., 2005). This 
was confirmed by findings from the plasma AUC/ileostomy trial (II) after 
ingestion of reduced 5-CH3-H4folate and folic acid.  
It remains unclear from findings in this thesis whether greater retention 
of folic acid in the liver can explain the difference in plasma kinetics 
between the folate forms, as suggested by Wright et al., (2005; 2003).  
Studies on transport of food folates have not been prioritised in molecular 
research, where the focus is merely on antifolate drugs. The main folate 
transporter in the small intestine, PCFT, was isolated only three years ago 
(Qiu et al., 2006). It may be that the hitherto rather unexplored field of 
molecular research may reveal in future explanations regarding the difference 
in plasma kinetics of reduced folate and folic acid. As previously discussed, 
some folate transporters have substantially higher affinity to reduced folates 
(PCFT, RCF), whereas others have higher affinity to folic acid (FR).  
The question from a public health perspective is whether differences in 
transporters can result in different tissues distribution of reduced folates and 
folic acid. This could partly explain the ambiguous role of folic acid in 
colorectal cancer (Kim, 2007). As malignant tumours are known to 
overexpress FR (Sega & Low, 2008) and FR has 10-fold higher affinity to 
folic acid than reduced folates (Kelemen, 2006), tumour growth is possibly 
accelerated by a high folic acid ingestion. 
Median plasma folate concentration in American women (post-
fortification) is ~25 nmol/L (McDowell et al., 2008) and twice as high as in 
Swedish women (Table 4). In contrast, the limited Swedish data on 
erythrocyte folate concentrations (Table 9) show the level to be higher or at 
least similar to that of American women (~600 nmol/L) (McDowell et al., 
2008). Could this be due to folic acid being a relative greater part of total 
folate intake in the USA (>200 µg/day) (Kalmbach et al., 2008; Quinlivan 
& Gregory, 2003) but a minor contributor to total folate intake in Sweden?  
Intervention studies with supplemental 5-CH3-H4folate have shown that 
reduced folates can improve erythrocyte folate concentrations more or 
equally efficient as folic acid (Lamers et al., 2006). Knowledge on post-dose 
folate distribution of different folates within the human body is still limited 
and further mechanistic studies - using doses of biological active food folate 
diastereoisomers and not racemates - are therefore needed.   
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The superior bioavailability of folic acid was not confirmed in the plasma 
AUC/ileostomy trial (II). Based on labeled folate content in stomal effluent 
the bioavailability appeared to be over 90% for both, 
13C5-5-CH3-H4folate 
and 
13C5-folic acid. Release of the added fortificants (
13C5-5-CH3-H4folate 
and 
13C5-folic acid) does not necessarily reflect release of endogenous food 
folates in the wholemeal bread accurately. Only by use of intrinsic labelling 
could this be studied. 
The pronounced lowering (>20%) of plasma total homocysteine 
concentration after consumption of five slices wholemeal bread (containing 
an additional folate dose of only ~70 µg/day) exemplifies a challenge of 
nutritional studies. As no significant effect was observed in the other folate 
status parameters, i.e. serum and erythrocyte folate concentrations, additive 
effects from intake of folate and other bread components, e.g. betain, could 
have caused this pronounced reduction in homocysteine concentrations 
(Alfthan et al., 2004). It could also be hypothesised that dietary fibre from 
the wholemeal bread affected the colon microflora (Keagy, 1990), which in 
turn could affect human folate status. 
In the post-dose stomal effluents, labelled folates comprised only one-fifth 
of the total folate content. Unlabelled folates in stomal effluents are 
suggested to originate from bile and other secretions, sloughed enterocytes 
and possibly to a small extent the colon microflora (Gregory & Quinlivan, 
2002), but the contribution of each of these sources is unknown.  
To conclude, folate research has hitherto identified the important 
physiological function of folates and the clinical implications of an 
insufficient intake. Furthermore, data on estimated intake of folates indicate 
that it may be inadequate in subgroups of the population but this was not 
always associated with an inadequate folate status.  
Folate bioavailability from different test foods and a complete meal was in 
this thesis estimated to be about 75-90% and positive effects from both 
interventions on folate status of healthy women could be demonstrated. This 
is in agreement with several recent intervention trials by others (Table 1b) 
and indicates that the general assumption of an inferior bioavailability of 
only 50 % of food folate (CDC, 2009; NNR, 2005) compared to 
supplemental folic acid might need to be reconsidered. It is therefore 
desirable that research focuses to identify factors affecting folate status, e.g. 
folate bioavailability, and the importance of these.  
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